US20080004561A1 - Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment - Google Patents

Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment Download PDF

Info

Publication number
US20080004561A1
US20080004561A1 US10/564,615 US56461505A US2008004561A1 US 20080004561 A1 US20080004561 A1 US 20080004561A1 US 56461505 A US56461505 A US 56461505A US 2008004561 A1 US2008004561 A1 US 2008004561A1
Authority
US
United States
Prior art keywords
dna
clone
sequence
oncological
blood plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/564,615
Inventor
Dmitry Genkin
Viktor Tets
Georgy Tets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/RU2003/000304 external-priority patent/WO2005007187A1/en
Application filed by Individual filed Critical Individual
Publication of US20080004561A1 publication Critical patent/US20080004561A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Definitions

  • the invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases when the main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof.
  • Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism.
  • Proposed method is based on completely new principle of therapeutic action, provide strong antitumor and antimicrobial efficacy and could be used in therapy of oncological diseases, different infections and non-infectious diseases.
  • Patent U.S. Pat. No. 5,952,170 disclose the determination of DNA content in blood plasma for diagnostic and prognostic purposes in course of cancer disease.
  • Patents U.S. Pat. No. 6,465,177 and U.S. Pat. No. 6,156,504 disclose the use of blood plasma DNA for mutation's determination in oncogenes and microsatellite gene regions, for genetic instability studying in tumors and the use of these results for diagnostic, monitoring and prognostic purposes in the course of disease.
  • DNase I chemotrypsine and desoxiribonuclease I
  • Torchilin V. P. (2001), Patent (U.S. Pat. No. 5,780,033), disclose the therapeutic use of autoantibodies that are able to bind with cytoplasmic and nuclear membranes of tumor cells and with protein-DNA complex coming from dead tumor cells. It is clear from the text of application that the disclosure relates solely to antibodies against protein antigenic determinants. In our case anti-DNA antibodies and anti-DNA abzymes are used. Moreover, therapy disclosed by authors was trended against phagocytosis of nucleosomes on the surface of tumor cells and that exclude the possibility of therapeutic regimes sufficient for binding and removal of circulating blood plasma DNA.
  • DNA can get into the outer environment as a result of cells death, for example in the focus of inflammation. DNA as polymer increases biofluids viscosity and that negatively influence the course of the disease, preventing elimination of toxins, pathogens and necrotic debris. It is known that-DNase (Gentech-Roch) “Pulmozyme” is used for Cystic Fibrosis treatment by inhalation. The therapeutic action is based on dilution of broncho-alveolar secret, and does not relate to breach of genetic information traffic.
  • Invention includes destruction or inactivation of circulating microbial DNA as method for treatment and prophylaxis of diseases caused by them.
  • One aspect of invention discloses the pharmaceutical compositions and non pharmaceutical methods of free circulating DNA destruction or inactivation in blood plasma of patients with oncological or infectious diseases.
  • Another invention aspect discloses treatment method of patients' with oncopathology, infections, somatic diseases and method of extension of life time, which are based on administration of pharmaceutical compounds or application of non pharmaceutical methods providing the destruction or inactivation to free circulating blood plasma DNA.
  • Another aspect of invention provide the way of treatment efficacy control, when said treatment is directed to destruction or inactivation of free circulating blood plasma DNA, then the monitoring of free circulating blood plasma DNA and determination of tumor-specific genetic markers or genetic microbial markers presence in blood plasma could be used for treatment efficacy control.
  • Source of such variability is thought to be a special modus operandy of tumor cells' genetic apparatus. It is characterized by increased frequency of spontaneous mutations while activity of reparative system is decreased and control system of genetic homeostasis is switched off (Schmutte C., et al., Anticancer Res., 1999, v 19, pp. 4665-4696).
  • mutator phenotype of tumor cells (Loeb L. A., Cancer Research, 2001, v61, pp. 3230-3239), dynamic heterogeneity within tumor cell clones (Heppner G. H. et al., International Review of Cytology, 1998, v177, pp. 1-56) and numerous rounds of selection in the course of progression (Cahill D. P. et al., Trends in Cell Biology, v9, pp. M57-M60 ; Rubin H., Adv Cancer Res, 2001, v83, pp. 159-207; P. Nowell, Seminars in Cancer Biology, v 12, 2002, pp. 261-266) lead to selection and following expansion of the most malignant tumor clones. According to this knowledge the modern methods of malignant neoplasm's treatment are based on principle of tumor cells destruction in patient organism.
  • Free circulating DNA in blood plasma of oncological patients is a messenger of such cooperative relations. It realizes intrapopulational interclonal transport of genes, which are responsible for “malignant phenotype” formation.
  • FIG. 1 Results of immunochemical staining of mice tumor's histological slices after administration of 5 day course of Doxorubicin therapy (2 mg/kg every day intravenous) and DNase 1 (0.5 mg/kg four times a day during 5 days).
  • Fresh blood plasma (not more than 3-4 hours after isolation) with anticoagulant (sodium citrate) addition was centrifuged on Ficoll-PlaquePlus (Amersham-Pharmacia) step at 1500 g for 20 minutes at room temperature.
  • Plasma (1 ⁇ 2 of all amount) was neatly isolated avoiding touching cells sediment on ficoll step and was centrifuged at 10 000 g for 30 minutes to eliminate cells and debris.
  • Supernatant was taken away not touching sediment and up to 1% of sarcosile, up to 50 mM of tris HCl pH 7,6, up to 20 mM EDTA, up to 400 mM NaCl and equal volume of phenol—chloroform mixture 1:1 were added.
  • Received emulsion was incubated at 65° C.
  • phenol-chloroform was separated by centrifuging at 5000 g during 20 minutes at room temperature. Deproteinization by phenol-chloroform method was identically repeated for three times after what water phase was processed by chloroform and after it by diethyl ether.
  • nucleic acids were separated by centrifuging at 10 000 g during 30 minutes. Sediment of nucleic acids was dissolved in buffer that consisted of 10 mM tris—HCl, pH 7,6, 5 mM EDTA and was inflicted on step made from chlorine cesium gradient (1M, 2.5M 5.7) in centrifuge test tube for SW60Ti rotor. DNA volume was 2 ml, volume of each CsCl step was 1 ml. Ultracentrifuging was done in L80-80 (Beckman) centrifuge for 3 hours at 250000 g. DNA was isolated according to fractions from the step's surface 5.7M. Fractions were dialized during 12 hours.
  • DNA presence in fractions was defined by agarose electrophoresis with DNA visualization by ethidium bromide.
  • DNA amount was spectrophotometrically estimated (Beckman DU 470) in cuvette with volume 100 mkl, using 220-320 nm spectrum. Average runout of DNA was 10-20 ng according to 1 ml of plasma.
  • DNA was deproteinized with the use of proteinase K (Sigma) at 65° C. for tightly-bound proteins elimination. After deproteinization DNA was processed by phenol-chloroform at 65° C. and sedimented by 2.5 volumes of ethanol during night. After it DNA was processed by EcoRI restrictase during 3 hours or by Pfu polymerase (Stratagene) at the presence of 300 mkM of all desoxynucleothydethreephosphates for “sticky” edges elimination. Completed DNA was phosphorylated by polynucleotide kinase T4 (30U, 2 hours).
  • Received samples/preparations were ligated in Bluescript (Stratagene), plasmid digested by EcoR1 or PvuII accordingly and dephosphorylated by alkaline phosphatase CIP (Fermentas) during 1 hour.
  • 1 mkg of vector and 0.1-0.5 mkg of serum DNA were usually used for ligation.
  • Ligation was done by Rapid Ligation Kit (Roche) use for 10 hours at 16° C. Volume of ligase mixture was 50 mkl.
  • Ligated library was transformed into DH12S (Life Technologies) cells with electroporator (BioRad) use. For transformation of one library 12-20 electroporation cuvettes were used.
  • Dilutions of the library at concentrations 10 ⁇ 4 , 10 ⁇ 5 and 10 ⁇ 6 were plated for control on dishes with 1.5% agar and LB media, supplemented with 100 mkg ⁇ ml ampicillin. In both cases library's representativeness was approximately 2-3 ⁇ 10 6 clones.
  • Theoretically set of DNA sequences that circulate in plasma should correspond to set of genome's DNA sequences.
  • apoptosis is accompanied by quantitative and nonspecific DNA degradation before its exit out of the cell, so the most wide spread DNA in plasma should be repetitive elements of genome in proportion that correspond to nonspecific degradation of DNA.
  • Such elements are L1 repeats, satellite DNA, Alu, MER, MIR, THE repeats and some others. Quantity of unique sequences should be small in accordance to their small percent in human genome they may be not detected in cloning DNA without PCR.
  • alpha-satellite DNA (30 clones). It is possible to say that that alpha-satellite DNA was the only highly repeated element from human genome, which behaves exactly as repeat in this material. The rest of highly repetitive elements were presented in material as one or several clones (L1 variant and MLT26), or were not found among patterns (MER, Alu, THE, MIR, ⁇ tilde over ( ⁇ ) ⁇ satellite). Based on today's knowledge one can assume that plasma blood composition for the most part should repeat composition of genome DNA, so listed repeats should be represented in the major part of clones while unique and moderately repeated consequences in analysis of such a small number of clones should not be recognized at all.
  • duplicones that were recently unknown, also support the evidence of special way of plasma DNA formation in patients with malignant tumor.
  • duplicones were found in human genome less then two years ago.
  • Known duplicones (Eichler E. E., et al., Genome Res, 1998, v8, pp. 791-808; Ji Y., et al., Genome Res, 2000, v. 10, pp. 597-610; Pujana M. A., et al., Genome Res, 2001, v. 11, pp.
  • 98-111 are extensive regions of DNA that were multiplied for several times in the frame of one chromosome (unlike other repeats that are randomly allocated in genome). Duplicones' formation and expansion is connected with different genetic syndromes (for example Prader-Willi/Angelmane syndrome), with multigenic families' evolution such as MHS (Shiina T., et al., Proc Nat Acad Sci USA, 1999, v. 96, pp. 13282-13287) and with chromosome instability in tumors.
  • MHS Manton-Willi/Angelmane syndrome
  • Blood plasma DNA of oncological patient is highly enriched with unique genes.
  • 55 out of 96 analyzed clones contain fragments of genome's unique sequences.
  • 14 out of 15 sequences with identified in functions refer to process of tumor progression and maintenance of “malignant phenotype”.
  • blood plasma DNA of healthy people and oncological patients for the most part contain unique fragments of human genome.
  • unique sequences of blood plasma DNA correspond to genes which products take part in the formation and maintenance of tumor cell's “malignant phenotype”.
  • DNA circulating in patient's blood can be messenger of horizontal genetic information transfer during the course of oncological diseases, assisting to accumulation and spreading of genes that are necessary for “malignant phenotype” formation and maintenance within population of tumor cells.
  • Somatic mosaicism is a condition that is a result of genetically non-identical somatic cells' presence in organism. Modern vision presents that many non tumor and noninfectious (so called somatic) human diseases (for example atherosclerosis, diabetes, nonspecific chronic lung diseases and so on), including aging process, are connected with appearance and spreading (expansion) in the process of individual development of somatic cells' clones that have mutant genes.
  • somatic tumor and noninfectious
  • somatic mosaicism's appearance There are two alternative models of somatic mosaicism's appearance. The first is appearance of somatic mosaicism as a result of numerous “de novo” mutations in polyclonal cellular pool. The second model is clonal expansion of mutant cells' clone (Khrapko K., et al., Muation Res., 2003, v. 522, pp. 13-19).
  • Bovine pancreatic DNase I Framas
  • human recombinant DNase I Dornase; Gentech
  • DNase I solution for injections were prepared by dissolving of DNase matrix solution in sterile phosphate buffer directly before administration. Cyclophosphamide and Doxorubicin were dissolved according to instruction.
  • mice Blood plasma DNA of tumor-bearing mice was received according to technique described above. Highly metastatic and low metastatic stains of mice' Luice lung carcinoma and Erlich carcinoma were used. Cells were cultivated in RPMI-1640 media with adding of 10% embryonic calf serum, 1% penicillin—streptomycin in 5% carbon dioxide atmosphere. For tumor induction in mice, cells were cultivated until the monolayer, than were detached with trypsin-EDTA solution. Cells were washed trice by centrifuging in phosphate buffer and were resuspensed until their concentration have become 0.5 ⁇ 10 7 /ml. Viability was defined by inclusion of methylene blue in hemocytometer. Suspensions that contained 95% of viable cells were used for administration to animals.
  • mice of C57B1 line and white not thoroughbred mice from “Rappolovo” animal house were used. Weight of animals was 24-26 grams. Animals were contained in cages, for 6-7 mice per one cage on a standard diet without water restriction. LLC cells in dose of 5 ⁇ 10 5 in 100 mkl of phosphate buffer were injected in soft tissues of thigh. Erlich tumor was subcutaneously replanted on the right side by injection of 0.2 ml 10% cells' suspension in isotonic sodium chloride solution.
  • DNA was isolated by method that is mentioned above. DNA amount was spectrophotometrically measured.
  • Group 1 10 mice transplanted with Erlich carcinoma (control).
  • mice transplanted with Erlich carcinoma 10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • mice transplanted with Erlich carcinoma mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 2 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • TGI tumor's growth inhibition
  • Tumor's size on the 7 day after transplantation The Tumor's Group volume TGI % P 1 86+/ ⁇ 12 — — 2 33 +/ ⁇ 6 61% p ⁇ 0.001 3 34 +/ ⁇ 7 60% p ⁇ 0.001
  • the data obtained indicates that tumor's growth is significantly inhibited by DNase injection.
  • DNA circulating in blood plasma of patients was the therapeutic target of DNase. Prolonged presence of DNase in blood plasma at catalytically effective concentrations is essential for provision of maximal therapeutic effect. According to that DNase myltiply administration should provide better therapeutic effect than the same total daily dose, administrated just as only two daily injections.
  • Group 1 10 mice transplanted with Erlich carcinoma (control).
  • mice transplanted with Erlich carcinoma 10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • mice transplanted with Erlich carcinoma mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • TGI tumor's growth inhibition
  • Tumor's size on the 7 day after transplantation The Tumor's volume T% P 1 98+/ ⁇ 14 — — 3 23 +/ ⁇ 6 76% P ⁇ 0.001 2 32 +/ ⁇ 6 67% P ⁇ 0.001
  • Received data indicates that tumor's growth is more inhibited by fractional (four times a day) administration of DNase at the same total daily dose than twice a day administration.
  • Blood plasma DNA concentration of mice from 3 group after end of treatment course was 38.5 ng/ml
  • mice from control group had 104.8 ng/ml
  • mice from the 2 group—55.1 ng/ml Blood plasma DNA concentration of healthy mice was 12.0 ng/ml (p ⁇ 0.01). So, multiply daily administrations of DNase lead to more significant decrease of blood plasma DNA level and greater tumor's growth inhibition in comparison with twice a day administration of the same total dose.
  • Group 1 10 mice transplanted with Erlich carcinoma (control).
  • mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg/kg dose once a day starting from 3 up to 7 day after tumor transplantation.
  • mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg/kg dose once a day starting from 3 up to 7 day after tumor transplantation. As well mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • mice replanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • TGI tumor's growth inhibition
  • Tumor's size on the 7 th day after transplantation Group Tumor's volume T% P 1 98 +/ ⁇ 14 — — 2 57 +/ ⁇ 10 42 P ⁇ 0.05 4 20 +/ ⁇ 6 78 P ⁇ 0.01 3 0 100%
  • Received data indicates that tumor's growth is less inhibited by Doxorubicin than by DNase.
  • Doxorubicin and DNase present synergism in their action leading to complete inhibition of tumor's growth (tumors were not found in any experimental animals).
  • Bacteria were sowed at 10 9 bacteria/ml concentrations and were incubated at 37° C. during 72 hours on synthetic M9 media that contains additives necessary for used bacteria strains. DNase was added in amount of 100 mkg/ml right after bacteria' inoculation. Identical volume of phosphate buffer was added to control. Selective vials were taken for analysis every 24 hours.
  • CFU colony-forming units
  • mice White not thoroughbred mice were used for experiment. Animals' weight was 24-26 grams. Pathogenic strain of Staphylococcus aureus VT-2003R at 1 ⁇ 10 10 bacteria/animal dose was inoculated to retroorbital sinus of animals. DNase was intraperitoneally administered. Isotonic solution of sodium chloride or Penicillin was administrated to control groups. Each experimental group contained 10 mice. Intraperitoneal administration of compound (DNAase) four times a day at 500 mkg/kg dose continued for 1-3 days after infection. Penicillin was intramusculary administrated. Efficiency of action was estimated by number of animals that stayed alive after the death of the last one in control group. All animals have died to the third day of the experiment in control group. Six animals stayed alive to the third day of the experiment in the group that administrated DNase. Protection was 67%. Received data specify an opportunity and efficiency of DNase use for infections' treatment.
  • Blood plasma DNA of oncological patients and blood plasma DNA of healthy donors differs not only by its genetic repertoire but also by its amount circulating in blood plasma. Table below presents data of blood plasma DNA contents at 10 oncological patients and at 10 healthy volunteers. DNA isolation from plasma and determination of its amount was done according to protocol mentioned above.
  • SCRAP Snf2-related CBP activator protein
  • RAMP RA-regulated nuclear matrix-associated protein
  • NFKB 1 nuclear factor of kappa light polypeptide gene enhancer
  • BAI3 brain-specific angiogenesis inhibitor 3
  • DNA from fresh blood serum (mixture of blood received from 5 volunteers ) was isolated by standard phenol-chloroform method.
  • DNA circulating in blood plasma of oncological patients can be destroyed or inactivated not only by DNA—digesting enzymes (for example by DNase), but also by other methods.
  • Anti-DNA antibodies were isolated from blood of patients with lupus erythematosus by Shuster A. M. method (Shuster A. M. et. al., Science, v. 256, 1992, pp. 665-667). Such anti-DNA antibodies were capable not only to bind DNA but also to hydrolyze it.
  • Group 1 mice transplanted with Erlich carcinoma (control).
  • mice transplanted withy Erlich carcinoma mice transplanted withy Erlich carcinoma. Mice were injected intravenously with fraction of human anti-DNA antibodies (Ig G) at 200 mkg dose on the third day after tumor transplantation.
  • Ig G human anti-DNA antibodies
  • mice transplanted withy Erlich carcinoma mice transplanted withy Erlich carcinoma. Mice were injected intravenously with fraction of human non specific immunoglobulin (Ig G) at 200 mkg dose on the third day after tumor transplantation.
  • Ig G human non specific immunoglobulin
  • TGO tumor's growth inhibition on the 7 th day after transplantation
  • DNA from plasma of mice with Erlich carcinoma was isolated on the 5th day after transplantation according to method mentioned above. Positively charged multilayer liposomes were used as adjuvants for immunization. DNA sample was mixed with liposomes (20 mkg of DNA in 1 mg of lipids).
  • mice Group 1—6 non immunized mice.
  • Group 2 6 mice immunized for three times with one week 5 interval by intradermal administration of 1 mkg DNA from blood plasma in 50 mkl of liposomal suspension containing 50 mkg of liposomes.
  • Group 3 6 mice immunized for three times with one week interval by intradermal administration of 50 mkl of liposomal suspension containing 50 mkg of liposomes without DNA.
  • mice immunized for three times with one week interval by intradermal administration of 1 mkg DNA from calf thymus (Sigma) in 50 mkl of liposomal suspension containing 50 mkg of liposomes.
  • Results of the experiment were estimated according to animal survival on the 30th and 50 th day after tumor's transplantation.
  • 30 day 50 day number of alive ⁇ (number of alive ⁇ number of dead in number of dead in Group group) group) 1 0-6 0-6 2 5-6 3-6 3 0-6 0-6 4 2-6 0-6
  • mice with replanted Erlich carcinoma by blood plasma DNA lead to significant increasing of animals' lifetime.
  • Biofilms of Escherichia coli and Staphylococcus aureus were used in experiments. Biofilms were washed off by phosphate buffer from agar. Cells and matrix were separated by centrifuging. Standard phenol-chloroform method was used for DNA extraction from matrix. DNA amount was estimated by spectrophotometric analysis with wave's length 260 nm (SF-46). Received DNA was researched by electrophoresis in 0.8% polyacrylamide gel with ethidium bromide staining.
  • Doxorubicin causes expression of P-glycoprotein in tumor tissue that is one of the main MDR (Multidrug Resistance) phenotype mediators. Immunohistochemical staining of mice's tumor histological cuts are listed below.
  • mice were subjected to course of 5 day therapy with Doxorubicin (2 mg/kg intravenously daily) or Doxorubicin+DNase I (0.5 mg/kg four times a day during 5 days)
  • mice mice (control).
  • Group 2 6 mice intravenously treated with Doxorubicin chemotherapy from 3 rd up to 8 th day at 2 mg/kg dose daily.
  • Group 3 6 mice intravenously treated with Doxorubicin chemotherapy from 3 rd up to 8 th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to Doxorubicin chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)
  • Tumor's size on the 8 th day after transplantation Group Tumor's size 1 127+/ ⁇ 13 2 67 +/ ⁇ 7 3 115 +/ ⁇ 20 4 75 +/ ⁇ 11 5 82 +/ ⁇ 9
  • mice with transplanted LLC tumor participated in the experiment.
  • mice transplanted with low metastatic LLC strain +intravenous administration of total DNA fraction from mice with transplanted highly metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7 th and 8 th day after transplantation)+intraperitoneal administration of DNase I at 1 mg/kg dose two times daily at 7 th and 8 th day after transplantation.
  • mice transplanted with highly metastatic LLC strain.
  • Received data indicates that blood plasma DNA from mice with highly metastatic LLC strain intensify metastasizing of low metastatic LLC strain.
  • mice mice (control).
  • mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 7 day after tumor transplantation.
  • mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 10 day after tumor transplantation.
  • mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 15 day after tumor transplantation.
  • mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 18 day after tumor transplantation.
  • Results of experiment were estimated according to animals' survival on the 30 and 50 day after tumor transplantation.
  • 30 day 50 day number of alive ⁇ (number of alive ⁇ number of dead in number of dead in Group group) group) 1 0-7 0-7 2 0-6 0-6 3 3-6 0-6 4 5-1 3-3 5 6-0 6-0
  • DNase I does not cause direct cytotoxic effect on tumor cells (in our in vitro experiments at concentration of 100 mkg/ml) and experimental data confirm that antitumor effect is connected with destruction of DNA in blood plasma and DNase's therapeutic effect increases with increasing of its treatment course duration.
  • mice 100 mice were transplanted with highly metastatic LLC strain. On the 9th day after transplantation, animals were euthanized and total blood plasma was taken. After isolation total fraction of blood plasma DNA was stored at ⁇ 20° C. in phosphate buffer.
  • mice with transplanted low metastatic LLC strain participated in the experiment.
  • Group 1 6 mice transplanted with low metastatic LLC strain.
  • mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7 th and 8 th day after transplantation 0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection.
  • the sample was photochemically disinfected (1 mkM of methylene blue was added with following irradiation by red light during 10 minutes (60 000 Lux).
  • mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7 th and 8 th day after transplantation 0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection.
  • the sample was passed through the column containing DEAE-cellulose for two times before administration.
  • mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7 th and 8 th day after transplantation 0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection. 1 mkg of fragment A of Ricin toxin was added to the sample before administration and sample was incubated at 370C for 1 hour.
  • Ricin toxin is representative of RIP toxins family (proteins that inactivate ribosomes) which are used for immunotoxin's creation. Besides their ability to inactivate ribosomes these proteins can deadenylate DNA.
  • catalytic subunit A of RIP II type should by delivered to cell by B subunit. Without B subunit A chain is not toxic but can be used for blood plasma DNA's inactivation due to its polynucleotide-adenylglicozidase activity.
  • mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7 th and 8 th day after transplantation 0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection.
  • Total DNA fraction was enzymatically methylated before administration (I. Muiznieks et. al., FEBS Letters, 1994, v. 344, pp. 251-254).
  • Received data indicates that all used methods inhibited ability of blood plasma DNA of mice with highly metastatic LLC tumor strain to increase metastasizing process of low metastatic LLC tumor strain.
  • HPRT gene Frequency of HPRT gene's mutations in blood T-lymphocytes was studied as a model of somatic mosaicism.
  • Human HPRT gene chromosome Xq26
  • Cloning was done according to Bigbee W. method (Bigbee W. Et al., Mutation Res., 1998, v. 397, pp. 119-136).
  • Lymphocytes from peripheral blood of 8 patients subjected to 3 week course of immunostimulating therapy by Neovir after surgical elimination of tumor were used for cloning. 4 patients out from 8 were additionally subjected to intravenous administration of human recombinant DNase I (200 mkg/kg dose 4 times a day during three weeks).
  • ⁇ tilde over ( ⁇ ) ⁇ cells of human embryonic pancreas and endothelial cells of human aorta were used for primary cell culture formation.
  • DNA isolated from plasma of patient with severe II-type diabetes complicated by systemic atherosclerosis (0.0025 mkg per 1 ml of culture media) was added to cell culture 24 hours after passage.
  • Blood plasma circulating DNA can be destructed, inactivated or eliminated from blood plasma by DNases, sorbents, antibodies and other methods which provide inactivation by destroying, binding or modification of circulating DNA.
  • Efficiency of the treatment directed to blood plasma DNA's destruction can be estimated by monitoring of DNA amount and amount of tumor's genetic markers in blood plasma of patient who receive such therapy.
  • Cloning and sequencing of blood plasma DNA from oncological patient's can be used for studying of genetic processes that take part in oncogenesis and identification of new genes connected with oncogenesis processes.
  • Cloning and sequencing of healthy people's blood plasma DNA can be used for studying of genome's operating in healthy individual and in the development of somatic diseases and in identification of new genes that are involved in these processes.
  • compositions containing components that inactivate by destroying, binding and modification the blood plasma DNA could be used for treatment of patients with oncological diseases, infections, somatic diseases and for prolongation of life time.
  • drug delivery systems are used providing maximal systemic circulations of the active component in blood plasma and its contact with DNA circulating in plasma.
  • the main way of administration is intravenous. But other ways of administration that provide coming of active component in to systemic circulation, such as subcutaneous, intramuscular, inhalation, intraperitoneal and others can also be used. Doses and regimes of administration are determined by nature of used active ingredient and way of administration. The effect is controlled by the level of DNA's contents and its dynamics in blood plasma, presence of tumor, infectious and other genetic markers, and appearing of positive clinical dynamics of disease.

Abstract

The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases whose main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and other diseases are also disclosed.

Description

    TECHNICAL FIELD
  • The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases when the main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and to prevent their relapses as well as for treatment of infections, atherosclerosis, diabetes and slowing the aging process. Proposed method is based on completely new principle of therapeutic action, provide strong antitumor and antimicrobial efficacy and could be used in therapy of oncological diseases, different infections and non-infectious diseases.
    • BACKGROUND ART
  • Populations of cancer cells, developing in patient's organism possess extremely high level of genetic plasticity that is much higher than that in normal cells. Genetic plasticity within cancer cells populations allows them to generate in course of disease the phenotypes which are resistant to immune and morphogenic control and which has the capacity for invasion and metastasis and are resistant to antitumor therapies. It is known, that selection and clonal expansion of tumor cells comprise the basis of biological and clinical tumor progression. According to that knowledge, the modern strategy of anticancer therapy is based on principles of tumor cell clones destruction in patient organism through chemotherapy, radiotherapy, immunotherapy, surgical elimination and by use of their combinations. Fundamental particularity of all these methods is that their sole therapeutic target is a tumor cell. The long term experience from clinical application of such therapy has shown that due to high genetic placticity the most malignant cells become insensitive to the specific therapy used before malignant neoplasm could be completely destroyed by said therapy.
  • There is a great medical need for new antitumor drugs less toxic than existing ones or can potentiate thre efficacy of existing methods. As well it is a need for new antitumor drugs that can decrease toxicity of currently available methods without decreasing of their efficacy.
  • The circulation of DNA molecules in blood plasma of cancer patients and healthy people was known from some publications (P. Anker et al., Clinica Chimica Acta, v. 313, 2001, pp. 143-146; Fedorov N. A. et. al., Bull. Exp. Biol. Med., v102,1986, pp 281-283. Patent (U.S. Pat. No. 5,952,170) disclose the determination of DNA content in blood plasma for diagnostic and prognostic purposes in course of cancer disease. Patents (U.S. Pat. No. 6,465,177 and U.S. Pat. No. 6,156,504) disclose the use of blood plasma DNA for mutation's determination in oncogenes and microsatellite gene regions, for genetic instability studying in tumors and the use of these results for diagnostic, monitoring and prognostic purposes in the course of disease.
  • Sugihara S. et al. (1990, 1993) studied
    Figure US20080004561A1-20080103-P00900
    chemotrypsine and desoxiribonuclease I (DNase I) enzymes influence on autologic and heterologic adhesion of tumor cells during their metastasing. They have shown that systemic introduction of DNase I could slow metastases development. The effect they find was therapeutically insufficient. Authors make conclusion that DNase I can be used together with surgical elimination of tumor for prevention of tumor cells' hematogenic dissemination. Authors meant the influence of DNase I on tumor cells' cytoplasmatic membrane but not on destruction of free circulating DNA. Accordingly, the regime and doses that were used could not cause the decrease of circulating DNA level.
  • Torchilin V. P. (2001), Patent (U.S. Pat. No. 5,780,033), disclose the therapeutic use of autoantibodies that are able to bind with cytoplasmic and nuclear membranes of tumor cells and with protein-DNA complex coming from dead tumor cells. It is clear from the text of application that the disclosure relates solely to antibodies against protein antigenic determinants. In our case anti-DNA antibodies and anti-DNA abzymes are used. Moreover, therapy disclosed by authors was trended against phagocytosis of nucleosomes on the surface of tumor cells and that exclude the possibility of therapeutic regimes sufficient for binding and removal of circulating blood plasma DNA.
  • There is practically no data concerning circulation of bacterial DNA in blood. In human organism all microorganisms exist in biofilm communities (Davey M. E. Otoole G. A. 2000. Microbial biofilms: from ecology to Molecular ganetics. Microbiol. Mol. Genet. 64:847-867). Biofilms are formed by bacterial cells, associated with extracellular matrix (Tez V. V. 1999. Formation and structure of mixed bacterial communities. APMIS, 107:645-654). In biofilm matrix we have found extracellular DNA that penetrates from living cells. Our data also indicates that bacterial DNA present in blood plasma of infected human and its quantities and composition could change subject to development of certain infections. It is also known that DNA can get into the outer environment as a result of cells death, for example in the focus of inflammation. DNA as polymer increases biofluids viscosity and that negatively influence the course of the disease, preventing elimination of toxins, pathogens and necrotic debris. It is known that-DNase (Gentech-Roch) “Pulmozyme” is used for Cystic Fibrosis treatment by inhalation. The therapeutic action is based on dilution of broncho-alveolar secret, and does not relate to breach of genetic information traffic.
  • There is no human or animal data, regarding the genetic composition of DNA, circulating in blood plasma. There is no data regarding blood plasma DNA analysis avoiding PCR (Polymerase Chain Reaction). The use of PCR can considerably distort the representation of DNA composition because of amplification primer's specificity. So far, the genetic analysis of plasma DNA in cancer patients were done by PSR method or blot hybridization and was directed to studying of genome changes in certain specific genome areas (for example in microsatellites and specific genes). (Sanchez-Cespedes M., et al., Ann Oncol, 1998, v9(1),pp 113-116; Sozzi G., et al., Clin Can Res, 1999, v5 (10), pp 2689-2692; Chen X. Q., et al., Nat Med, 1996, v2(9), pp 1033-1035).
  • Thus, there is no data available about genetic repertoire of DNA which circulates in blood plasma of patients with oncopathology, infections, somatic pathology and healthy people, about the biological role of of blood plasma circulating DNA and about possible therapeutic effect of blood plasma circulating DNA destruction or inactivation in these diseases treatment.
    • DISCLOSURE OF THE INVENTION
  • As a result of our work upon the invention we have unexpectedly found that blood plasma circulating DNA from oncological patients contain unique quantitative and qualitative repertoire of genes and regulatory genetic elements, which is strongly different from that of human genome. Circulating blood plasma DNA of oncological patients for the most part contains unique human genes, including genes that are associated with maintenance and formation of malignancy.
  • It was shown that circulating blood plasma DNA of patients with oncopathology participates in intercellular transport of genetic information within tumor cells' population in patient organism. Current invention disclosure methods of free blood plasma circulating DNA destruction and inactivation which lead to suppression of tumor development in host organism. The invention also disclosure new method for identification of genomic structures which are involved in tumor progression and human genome operation. This aspect of invention is connected with DNA samples isolation from blood plasma of healthy people and patients with oncological diseases, cloning and sequencing them.
  • It was found out that DNA from biofilm matrix secreted by different bacteria enters into the blood and biological fluids of human and animals. It was stated that the presence of extracellular DNA is one of conditions necessary for microbial infection development.
  • Invention includes destruction or inactivation of circulating microbial DNA as method for treatment and prophylaxis of diseases caused by them.
  • It was also found out that DNA circulating in blood of healthy people play role in somatic mosaicism's development. Binding, destruction or inactivation of that DNA could suppress the somatic mosaicism development. Binding, destruction or inactivation of circulating blood plasma DNA could be of therapeutic value in treatment of diseases which progression is linked with somatic mosaicism development.
  • One aspect of invention discloses the pharmaceutical compositions and non pharmaceutical methods of free circulating DNA destruction or inactivation in blood plasma of patients with oncological or infectious diseases.
  • Another invention aspect discloses treatment method of patients' with oncopathology, infections, somatic diseases and method of extension of life time, which are based on administration of pharmaceutical compounds or application of non pharmaceutical methods providing the destruction or inactivation to free circulating blood plasma DNA.
  • Another aspect of invention provide the way of treatment efficacy control, when said treatment is directed to destruction or inactivation of free circulating blood plasma DNA, then the monitoring of free circulating blood plasma DNA and determination of tumor-specific genetic markers or genetic microbial markers presence in blood plasma could be used for treatment efficacy control.
  • Methods of patients' treatment with oncopathology and infectious diseases based on pharmaceutical compounds administration or use of non pharmaceutical methods that lead to destruction or inactivation of free circulating blood plasma DNA, when such treatment is combined with use of antitumor or antimicrobial therapy were disclosed.
  • Genetic placticity of tumor cells, which allows them to accumulate and maintain signs that comprise “malignant phenotype”, reveals itself on genetic and chromosomal levels by loss, acquiring or changing of DNA consequences, starting from single nucleoside up to whole chromosomes (Loeb K. R. et. al., Carcinogenesis, v21, 2000, pp. 379-385).
  • Source of such variability is thought to be a special modus operandy of tumor cells' genetic apparatus. It is characterized by increased frequency of spontaneous mutations while activity of reparative system is decreased and control system of genetic homeostasis is switched off (Schmutte C., et al., Anticancer Res., 1999, v 19, pp. 4665-4696).
  • It is thought that “mutator” phenotype of tumor cells (Loeb L. A., Cancer Research, 2001, v61, pp. 3230-3239), dynamic heterogeneity within tumor cell clones (Heppner G. H. et al., International Review of Cytology, 1998, v177, pp. 1-56) and numerous rounds of selection in the course of progression (Cahill D. P. et al., Trends in Cell Biology, v9, pp. M57-M60 ; Rubin H., Adv Cancer Res, 2001, v83, pp. 159-207; P. Nowell, Seminars in Cancer Biology, v 12, 2002, pp. 261-266) lead to selection and following expansion of the most malignant tumor clones. According to this knowledge the modern methods of malignant neoplasm's treatment are based on principle of tumor cells destruction in patient organism.
  • In the process of investigation we have unexpectedly found that accumulation of genetic changes that are essential for “malignant phenotype” formation in clinically advanced tumor is a result of cooperative interclonal interaction inside population of tumor cells in patients' organism, based on horizontal transfer of genetic information
  • Free circulating DNA in blood plasma of oncological patients is a messenger of such cooperative relations. It realizes intrapopulational interclonal transport of genes, which are responsible for “malignant phenotype” formation.
  • Destruction or inactivation of free blood plasma circulating DNA will lead to inability of tumor cells to maintain necessary level of genetic variability in organism and loss ability to maintain “malignant phenotype” (growth, metastasing, insensitivity to therapy). Such therapeutic intervention has its own therapeutic value as well as it increases efficacy of traditional therapeutic methods.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • P-glycoprotein expression in murine tumors
  • FIG. 1 Results of immunochemical staining of mice tumor's histological slices after administration of 5 day course of Doxorubicin therapy (2 mg/kg every day intravenous) and DNase 1 (0.5 mg/kg four times a day during 5 days).
      • A—Doxorubicin+DNase
      • B—Doxorubicin
    PREFERRED EMBODIMENT
  • Isolation of free circulating DNA from blood plasma.
  • Fresh blood plasma (not more than 3-4 hours after isolation) with anticoagulant (sodium citrate) addition was centrifuged on Ficoll-PlaquePlus (Amersham-Pharmacia) step at 1500 g for 20 minutes at room temperature. Plasma (½ of all amount) was neatly isolated avoiding touching cells sediment on ficoll step and was centrifuged at 10 000 g for 30 minutes to eliminate cells and debris. Supernatant was taken away not touching sediment and up to 1% of sarcosile, up to 50 mM of tris HCl pH 7,6, up to 20 mM EDTA, up to 400 mM NaCl and equal volume of phenol—chloroform mixture 1:1 were added. Received emulsion was incubated at 65° C. for 2 hours than phenol-chloroform was separated by centrifuging at 5000 g during 20 minutes at room temperature. Deproteinization by phenol-chloroform method was identically repeated for three times after what water phase was processed by chloroform and after it by diethyl ether.
  • Organic solvents' separation was done by centrifuging at 5000 g during 15 minutes. Equal part of isopropanol was added to water phase and incubated during night at 0° C.
  • After sedimentation nucleic acids were separated by centrifuging at 10 000 g during 30 minutes. Sediment of nucleic acids was dissolved in buffer that consisted of 10 mM tris—HCl, pH 7,6, 5 mM EDTA and was inflicted on step made from chlorine cesium gradient (1M, 2.5M 5.7) in centrifuge test tube for SW60Ti rotor. DNA volume was 2 ml, volume of each CsCl step was 1 ml. Ultracentrifuging was done in L80-80 (Beckman) centrifuge for 3 hours at 250000 g. DNA was isolated according to fractions from the step's surface 5.7M. Fractions were dialized during 12 hours. mM tris-HCl, pH 7,6, 1 mM EDTA at 4° C. will be added. DNA presence in fractions was defined by agarose electrophoresis with DNA visualization by ethidium bromide. DNA amount was spectrophotometrically estimated (Beckman DU 470) in cuvette with volume 100 mkl, using 220-320 nm spectrum. Average runout of DNA was 10-20 ng according to 1 ml of plasma.
  • Cloning and sequencing of blood plasma DNA.
  • We have developed new method of DNA isolation and cloning from blood plasma, that allows to construct not amplified plasmide library of such DNA with representativeness up to million clones with average size 300-500 base pair isolated from 50 ml of blood, even taking into account significant amount of elevated liposaccharides level and non identified mixtures that troubled purification of nucleic acids. So representative analysis can be done with less amount of plasma pattern—10-20 ml depending on pathological contaminates' presence.
  • Isolated according to above-mentioned method DNA was deproteinized with the use of proteinase K (Sigma) at 65° C. for tightly-bound proteins elimination. After deproteinization DNA was processed by phenol-chloroform at 65° C. and sedimented by 2.5 volumes of ethanol during night. After it DNA was processed by EcoRI restrictase during 3 hours or by Pfu polymerase (Stratagene) at the presence of 300 mkM of all desoxynucleothydethreephosphates for “sticky” edges elimination. Completed DNA was phosphorylated by polynucleotide kinase T4 (30U, 2 hours). Received samples/preparations were ligated in Bluescript (Stratagene), plasmid digested by EcoR1 or PvuII accordingly and dephosphorylated by alkaline phosphatase CIP (Fermentas) during 1 hour. 1 mkg of vector and 0.1-0.5 mkg of serum DNA were usually used for ligation. Ligation was done by Rapid Ligation Kit (Roche) use for 10 hours at 16° C. Volume of ligase mixture was 50 mkl. Ligated library was transformed into DH12S (Life Technologies) cells with electroporator (BioRad) use. For transformation of one library 12-20 electroporation cuvettes were used. Dilutions of the library at concentrations 10−4, 10−5 and 10−6 were plated for control on dishes with 1.5% agar and LB media, supplemented with 100 mkg\ml ampicillin. In both cases library's representativeness was approximately 2-3×106 clones.
  • Theoretically set of DNA sequences that circulate in plasma should correspond to set of genome's DNA sequences. Usually cells apoptosis is accompanied by quantitative and nonspecific DNA degradation before its exit out of the cell, so the most wide spread DNA in plasma should be repetitive elements of genome in proportion that correspond to nonspecific degradation of DNA.
  • Such elements are L1 repeats, satellite DNA, Alu, MER, MIR, THE repeats and some others. Quantity of unique sequences should be small in accordance to their small percent in human genome they may be not detected in cloning DNA without PCR.
  • Blood plasma DNA library of oncological patient with clinically advanced tumor stage.
  • We have constructed blood plasma DNA library of patient with diagnosed advanced stage mesothelioma. Representativeness of library was 8.5×105 clones, that is a good result, taking into account rather small amount of DNA (5 □g) received after purification from non character for healthy donors liposaccharides that were in extremely high concentrations at plasma of patient.
  • We have got the unexpected results after analysis of 96 clones with length from 300 up to 1000 base pairs. (It is necessary to mention that only one clone was not identified as human DNA. For all others correspondent information from HumanGenBank that identifies DNA of these clones as human DNA was received.) As mentioned above, according to data from literature it is logically to assume that there will be a lot of highly repetitive elements in DNA samples.
  • But at least 55 out of 96 clones presented unique sequences of human DNA. Taking into account real ratio of repetitive and unique elements of human genome (95% to 5%) it is obvious that blood plasma DNA repertoire of this patient differs a lot from human genomic DNA repertoire. In this sample an abrupt enrichment by unique DNA sequences is observed.
  • For 15 out of 55 unique DNA fragments that were identified during sequencing of 96 clones from the library of blood plasma DNA, functions or product of correspondent gene were identified. Tables 1-15 present list of these sequences and information about their participation in formation and maintenance of “malignant phenotype”.
    TABLE 1
    Participation in
    Clone Product oncogenesis Source
    Clone Member of G Playing major role in Steeg P. S., Nat
    24 protein - coupled cancer cell signalling. Rew
    receptor family Linked with cell Cancer, 2003, v. 3, pp.
    transformation, 55-63.
    supression of Raj G. V., J
    apoptosis, hormone Urology, 2002,
    independence and v. 167, pp. 1458-
    metastasis 1463.
    Hoff A. O.,
    Neoplasia, 1999
    v. 1, pp. 485-491.
  • TABLE 2
    Participation in
    Clone Product oncogenesis Source
    Clone Snf2-coupled Transription activator. Thaete C., Hum
    43 CBP activator Family members Mol
    protein (SCRAP) linked with synovial Genet, 1999, v. 8, pp.
    sarcoma and 585-91.
    leukaemia Monroy M, A., J
    development Biol
    Chem,. 2001, v. 276,
    pp. 40721-40726
    Lee D. W., Cancer
    Res., 2000,
    v. 60, pp. 3612-
    3622.
  • TABLE 3
    Participation in
    Clone Product oncogenesis Source
    Clone SRY-box Transcription Graham J. D., J
    51 containing gene modulator. Expressed Mol endocrinol,
    during embryogenesis. 1999, v. 22, pp. 295-
    Family members 304.
    linked with Lee C. J., J
    medulloblastomas, Neurooncol,
    gonadal tumors, highly 2002, v. 57, pp. 201-
    metastatic melanoma. 214.
    Uehara S., Cancer
    Genet
    Cytogenet, 1999, v.
    113., pp. 78-84.
    Tani M., Genomics,
    1997, v. 39, pp. 30-
    37
  • TABLE 4
    Participation in
    Clone Product oncogenesis Source
    Clone Protein-tyrosine Family members Hunter T., Philos
    72 kinase playing major role in Trans R Soc Lond
    cancer. Some PTK are B Biol Sci,
    cellular specific 1998, v. 353., pp.
    oncogenes products. 583-605.
    Scheijen
    B., Oncogene,
    2002, v. 21., pp.
    3314-3333.
  • TABLE 5
    Participation in
    Clone Product oncogenesis Source
    Clone Fibroblast Family members Chen W. T,
    83 activation protein playing role in cancer Enzyme
    alpha; cell surface invasion and Protein, 1996, v. 49.,
    serine protease metastasis. The pp. 59-71.
    product is active in Scanlan M. J., Proc
    cancer stroma and Nat Acad Sci USA,
    different carcinomas. 1994, v. 91,
    pp. 5657-5661.
    Mathew S.,
    Genomics,
    1995, v. 25, pp. 335-
    337.
  • TABLE 6
    Participation in
    Clone Product oncogenesis Source
    Clone Brain testican Proteoglycan with Genini M.,
    86 unknown function. Int J Cancer,
    Linked with neoplastic 1996, v. 66, pp. 571-
    phenotype of 577.
    embryonal
    rhabdomyosarcoma
    cells.
  • TABLE 7
    Participation in
    Clone Product oncogenesis Source
    Clone KRAB domain, Family members are Oguri T.,
    152 Zn-finger proteins known as transcription Gene, 1998, v. 222,
    repressors. Linked pp. 61-67
    with early Gou D. M., Biochim
    embryogenesis, Biophys Acta,
    neuroblastoma, Ewing 2001, v. 1518, pp.
    sarcoma, 306-310
    Tcell lymphoma, in Margolin J. F., Proc
    progression and Nat Acad Sci USA,
    chemoresistance in 1994, v/91, pp. 4509-
    lung cancer. 4513.
    Bellefroid
    E. J., EMBO J,
    1993, v. 12, pp.
    1363-1374
    Gonzales-Lamuno
    D., Pediatr Pathol
    Mol Med,
    2002, v. 21, pp.
    531-540.
    Marilee J. W., Gene,
    1994, v. 152, pp.
    227-232.
  • TABLE 8
    Participation in
    Clone Product oncogenesis Source
    Clone Antigen linked Antigen recognized by J. Immunol. 166(4),
    190 with melanoma autologous tumor 2871-2877, 2001
    infiltrating
    lymphocytes.
  • TABLE 9
    Participation in
    Clone Product oncogenesis Source
    Clone N-cadherin Cell adhesion Hazan R. B., J Cell
    167 molecule with major Biol,
    role in cancer growth, 2000, v. 148, pp.
    invasion and 779-790.
    metastasis. Li G., Cancer Res,
    2001, v. 61, pp.
    3819-3825.
    Tran N. L., J Biol
    Chem,
    2002, v. 277, pp.
    32905-32914.
  • TABLE 10
    Participation in
    Clone Product oncogenesis Source
    Clone FAF1: Fas Phosphoprotein known Jensen H. H., Int J
    197 associated factor to be the proapoptosis Biochem Cell Biol,
    1 factor. 2001, v. 33, pp. 577-
    589.
    Ryu S. W., Biochem
    Biophys Res
    Commun,
  • TABLE 11
    Participation in
    Clone Product oncogenesis Source
    Clone Interleukin 7 Proposed as essential Trinder P., Int J
    114 paracrine\autocrine Oncol,
    growth factor for 1999, v. 14, pp. 23-
    variety of cancers. 31.
    Cosenza L., Cell
    Signalling,
    2002, v. 14, pp. 317-
    325.
  • TABLE 12
    Participation in
    Clone Product oncogenesis Source
    Clone DEAD Box RNA Family members Iggo R. D., Mol Cell
    208 helicase-like involved to RNA Biol,
    protein methabolism. Linked 1991, v. 11, pp. 1326-
    to exponential cell 1333.
    growth in cancer. Causevic
    M., Oncogene,
    2001, v. 20, pp. 7734-
    7743.
  • TABLE 13
    Participation in
    Clone Product oncogenesis Source
    Clone Lipin 1 One of tumor cells' Brachat A. et. al.,
    97 response regulators on Oncogene,
    cytotoxic compounds. 2002, v. 21, pp. 8361-
    8371
  • TABLE 14
    Participation in
    Clone Product oncogenesis Source
    Clone Dynein Takes part in transport Bull J. H., et. al., Br J
    121 of p53 protein, is Cancer, 2001, v. 84, pp.
    hypersecreted at 1512-1519.
    cancer of prostate and Giannakakou P.,
    hepatocellular cancer. et. al.,
    Nat Cell Biol,
    2000, v. 2, pp. 709-
    717
    Jiang J., et. al., Gene,
    2001, v. 281, pp. 103-
    113.
  • TABLE 15
    Participation in
    Clone Product oncogenesis Source
    Clone Ramp protein Linked with human Cheung W. M.,
    178 embrional carcinoma et. al.,
    cells' development. J Biol Chem, 2001,
    v. 276, pp. 17083-
    17091
  • In this way 14 out of 15 sequences with identified function or protein that encodes different products (protein kinases, growth factors, proteinases, adhesive molecules and regulatory nuclear proteins) are described in literature as related to “malignant phenotype” formation and maintenance. Only product of 197th clone identified as pro-apoptotic factor is not clearly linked with malignant progression. Though there is data concerning relationship between high apoptotic activity of tumor with its progression (Nishimura R., et al., J Surg Oncol, 1999, v. 71, pp. 226-234) and possible role of apoptotic inductors in formation and maintenance of immunosupression in malignant growth (O'Connel J., et al., Dis Esophagus, 1999, v. 12, pp. 83-89).
  • The most significant presence from repetitive elements in this material was alpha-satellite DNA (30 clones). It is possible to say that that alpha-satellite DNA was the only highly repeated element from human genome, which behaves exactly as repeat in this material. The rest of highly repetitive elements were presented in material as one or several clones (L1 variant and MLT26), or were not found among patterns (MER, Alu, THE, MIR, {tilde over (□)}satellite). Based on today's knowledge one can assume that plasma blood composition for the most part should repeat composition of genome DNA, so listed repeats should be represented in the major part of clones while unique and moderately repeated consequences in analysis of such a small number of clones should not be recognized at all. Received result clearly indicates on special way of plasma DNA formation in oncological patients. Another unexpected result is that of finding in the material of two new moderately repeated sequences—duplicones, that were recently unknown, also support the evidence of special way of plasma DNA formation in patients with malignant tumor. For the first time duplicones were found in human genome less then two years ago. Known duplicones (Eichler E. E., et al., Genome Res, 1998, v8, pp. 791-808; Ji Y., et al., Genome Res, 2000, v. 10, pp. 597-610; Pujana M. A., et al., Genome Res, 2001, v. 11, pp. 98-111) are extensive regions of DNA that were multiplied for several times in the frame of one chromosome (unlike other repeats that are randomly allocated in genome). Duplicones' formation and expansion is connected with different genetic syndromes (for example Prader-Willi/Angelmane syndrome), with multigenic families' evolution such as MHS (Shiina T., et al., Proc Nat Acad Sci USA, 1999, v. 96, pp. 13282-13287) and with chromosome instability in tumors.
  • It is necessary to mention that analysis of clones received from blood plasma DNA of patient has given us unexpected results.
  • Blood plasma DNA of oncological patient is highly enriched with unique genes. 55 out of 96 analyzed clones contain fragments of genome's unique sequences. 14 out of 15 sequences with identified in functions refer to process of tumor progression and maintenance of “malignant phenotype”.
  • Strong impoverishment of the most wide spread human repeat such as MER, Alu, THE, MIR, {tilde over (□)}satellites is found in plasma DNA material.
  • Finding of two consequences with previously unknown duplicones' characteristics indicates on duplicones' representativeness in such DNA samples.
  • DNA library of healthy donor's blood plasma.
  • For method's value proof of blood plasma DNA cloning and sequencing for identification of genome's unique genetic consequences we have constructed DNA library of healthy donor's blood plasma. It is known that plasma of clinically healthy people also contains DNA but in significantly less amount than plasma of oncological patients (Shapiro B., et al., Cancer, 1983, v. 51, pp. 2116-2120).
  • Representativeness of library was near 8×105 clones. We have got interesting result after analysis of 70 clones with length from 300 up to 1000 base pairs. We found out that 58 out of 70 analyzed clones are unique DNA sequences of human genome. After searching the HumanGenBank, we identified the function or product of correspondent gene for 14 out of 58 unique DNA fragments.
  • Only 12 clones contained fragments of repetitive sequences, herewith without of alpha-satellite DNA dominance.
  • So, it was unexpectedly found out that blood plasma DNA of healthy people and oncological patients for the most part contain unique fragments of human genome. In the case of oncological pathology unique sequences of blood plasma DNA correspond to genes which products take part in the formation and maintenance of tumor cell's “malignant phenotype”.
  • Basing on this unexpected discovery we have suggested that DNA circulating in patient's blood can be messenger of horizontal genetic information transfer during the course of oncological diseases, assisting to accumulation and spreading of genes that are necessary for “malignant phenotype” formation and maintenance within population of tumor cells.
  • Somatic mosaicism is a condition that is a result of genetically non-identical somatic cells' presence in organism. Modern vision presents that many non tumor and noninfectious (so called somatic) human diseases (for example atherosclerosis, diabetes, nonspecific chronic lung diseases and so on), including aging process, are connected with appearance and spreading (expansion) in the process of individual development of somatic cells' clones that have mutant genes. (Youssoufian H., et al., Nature Rew. Genet., 2002, v. 3, pp. 748-758; J. Vijg, Mutation Res., 2000, v. 447, pp. 117-135; R. Erickson, Mutation Res., 2003, v. 543, pp. 125-136; Andreassi M., Mutation Res., 2003, v. 543, pp. 67-87; Anderson G., et al., Trends in Pharmacological Sci., 2003., v. 24, pp. 71-76).
  • Bright example of such process is progression of mitochondrial heteroplasmia (expansion of mutant mitochondrial DNA) at different diseases and in the aging process (E. Jazin et al., Proc Nat Acad Sci USA, 1996, v. 93, pp. 12382-12387; Michikawa Y. et al., Science, 1999, v. 286, pp. 774-779; Calloway C. et al., Am J Hum Gen, 2000, v. 66, pp. 1384-1397).
  • There are two alternative models of somatic mosaicism's appearance. The first is appearance of somatic mosaicism as a result of numerous “de novo” mutations in polyclonal cellular pool. The second model is clonal expansion of mutant cells' clone (Khrapko K., et al., Muation Res., 2003, v. 522, pp. 13-19).
  • In the process of work above the invention we have found that DNA circulating in the blood of healthy people play significant role in somatic mosaicism's development and its binding, destruction or inactivation inhibits development of somatic mosaicism. Binding, destruction or inactivation of circulating in blood plasma DNA provides treatment effect at diseases which appearance is connected with somatic mosaicism's development.
  • Examples that are mentioned later indicates role of circulating in blood of oncological patients DNA in the development of tumor's resistance to chemotherapy, development of metastasing process, in sepsis development and in some other pathological conditions. High therapeutic effect of blood plasma DNA's binding, destruction or inactivation is found.
  • Role of Free Circulating DNA in Tumor Progression
  • Materials and Methods.
  • Bovine pancreatic DNase I (Fermentas) and human recombinant DNase I (Dornase; Gentech) were used. DNase I solution for injections were prepared by dissolving of DNase matrix solution in sterile phosphate buffer directly before administration. Cyclophosphamide and Doxorubicin were dissolved according to instruction.
  • In series of in vitro experiments we have not seen any suppressive effect of DNase I on tumor cells' growth (DNase I concentration was up to 100 mkg/ml).
  • Blood plasma DNA of tumor-bearing mice was received according to technique described above. Highly metastatic and low metastatic stains of mice' Luice lung carcinoma and Erlich carcinoma were used. Cells were cultivated in RPMI-1640 media with adding of 10% embryonic calf serum, 1% penicillin—streptomycin in 5% carbon dioxide atmosphere. For tumor induction in mice, cells were cultivated until the monolayer, than were detached with trypsin-EDTA solution. Cells were washed trice by centrifuging in phosphate buffer and were resuspensed until their concentration have become 0.5×10 7/ml. Viability was defined by inclusion of methylene blue in hemocytometer. Suspensions that contained 95% of viable cells were used for administration to animals.
  • Mice of C57B1 line and white not thoroughbred mice from “Rappolovo” animal house were used. Weight of animals was 24-26 grams. Animals were contained in cages, for 6-7 mice per one cage on a standard diet without water restriction. LLC cells in dose of 5×105 in 100 mkl of phosphate buffer were injected in soft tissues of thigh. Erlich tumor was subcutaneously replanted on the right side by injection of 0.2 ml 10% cells' suspension in isotonic sodium chloride solution.
  • In some experiments DNA presence in blood plasma of mice was studied.
  • DNA was isolated by method that is mentioned above. DNA amount was spectrophotometrically measured.
  • The invention is illustrated by following examples.
    • EXAMPLE 1
  • Influence of DNase I Administrated Twice a Day on Erlich Tumor Growth at Mice
  • Group 1—10 mice transplanted with Erlich carcinoma (control).
  • Group 2—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • Group 3—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 2 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • Results of experiments were estimated according to tumor's growth inhibition (TGI) that were expressed in percents to control data received at last day of DNase injection with standard formula using.
  • Tumor's size on the 7 day after transplantation.
    Tumor's
    Group volume TGI % P
    1  86+/−12 — —
    2 33 +/− 6 61% p < 0.001
    3 34 +/− 7 60% p < 0.001
  • The data obtained indicates that tumor's growth is significantly inhibited by DNase injection.
    • EXAMPLE 2 Inhibition of Erlich Tumor Growth by Use of Different Schemes of DNase Administration
  • In our experiments DNA circulating in blood plasma of patients was the therapeutic target of DNase. Prolonged presence of DNase in blood plasma at catalytically effective concentrations is essential for provision of maximal therapeutic effect. According to that DNase myltiply administration should provide better therapeutic effect than the same total daily dose, administrated just as only two daily injections.
  • Group 1—10 mice transplanted with Erlich carcinoma (control).
  • Group 2—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 1 mg/kg dose in 200 ml of phosphate buffer twice a day starting from 3 up to 7 day after tumor transplantation.
  • Group 3—10 mice transplanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • Results of experiments were estimated according to tumor's growth inhibition (TGI) that were expressed in percents to control data received at last day of DNase injection with standard formula using
  • Tumor's size on the 7 day after transplantation.
    Group Tumor's volume T% P
    1  98+/−14 — —
    3 23 +/− 6 76% P < 0.001
    2 32 +/− 6 67% P < 0.001
  • Received data indicates that tumor's growth is more inhibited by fractional (four times a day) administration of DNase at the same total daily dose than twice a day administration. Blood plasma DNA concentration of mice from 3 group after end of treatment course was 38.5 ng/ml, mice from control group had 104.8 ng/ml and mice from the 2 group—55.1 ng/ml. Blood plasma DNA concentration of healthy mice was 12.0 ng/ml (p<0.01). So, multiply daily administrations of DNase lead to more significant decrease of blood plasma DNA level and greater tumor's growth inhibition in comparison with twice a day administration of the same total dose.
    • EXAMPLE 3 Combined Use of DNase and Antitumor Doxorubicin Compound
  • Group 1—10 mice transplanted with Erlich carcinoma (control).
  • Group 2—10 mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg/kg dose once a day starting from 3 up to 7 day after tumor transplantation.
  • Group 3—10 mice replanted with Erlich carcinoma. Mice were intravenously injected with Doxorubicin at 2 mg/kg dose once a day starting from 3 up to 7 day after tumor transplantation. As well mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • Group 4—10 mice replanted with Erlich carcinoma. Mice were intraperitoneally injected with DNase at 0.5 mg/kg dose in 200 ml of phosphate buffer four times a day starting from 3 up to 7 day after tumor transplantation.
  • Results of experiments were estimated according to tumor's growth inhibition (TGI) that were expressed in percents to control data received at last day of DNase injection with standard formula using.
  • Tumor's size on the 7th day after transplantation.
    Group Tumor's volume T% P
    1 98 +/− 14 — —
    2 57 +/− 10 42 P < 0.05
    4 20 +/− 6  78 P < 0.01
    3 0 100%
  • Received data indicates that tumor's growth is less inhibited by Doxorubicin than by DNase. Combined use of Doxorubicin and DNase present synergism in their action leading to complete inhibition of tumor's growth (tumors were not found in any experimental animals).
    • EXAMPLE 4 Influence of DNase on Bacterial Biofilm Formation
  • For estimation of possible mechanisms of DNase action on bacteria' interactions with host's organism we have estimated its influence on biofilm formation.
  • Experiments were performed on biofilm models, received at laboratory cultivation on the surface of glass. Non-relative Gram-positive (Staphylococcus aureus VT-209) and Gram-negative (Escherichia coli ATCC25922) bacteria were used.
  • Bacteria were sowed at 109 bacteria/ml concentrations and were incubated at 37° C. during 72 hours on synthetic M9 media that contains additives necessary for used bacteria strains. DNase was added in amount of 100 mkg/ml right after bacteria' inoculation. Identical volume of phosphate buffer was added to control. Selective vials were taken for analysis every 24 hours.
  • Glasses were washed by PBS buffer, fixed, stained with methylene blue and studied with the use of light microscopy.
  • As a result it was found out that in DNase presence normal biofilm was not formed. Only adhesion of single microorganisms to the glass that have not lead to the formation of microcolonies and biofilms was observed.
  • Control sowings from vials for definition of colony-forming units (CFU) have shown that at DNase presence there is no death of cells leading to decrease of CFU's numbers in comparison with controls. Received data indicates that DNase do not cause death of Staphylococci and Escherichia, but prevent their cooperative behavior that leads to biofilm formation.
    • EXAMPLE 5 DNase' Use for Treatment of the Experimental Sepsis
  • White not thoroughbred mice were used for experiment. Animals' weight was 24-26 grams. Pathogenic strain of Staphylococcus aureus VT-2003R at 1×1010 bacteria/animal dose was inoculated to retroorbital sinus of animals. DNase was intraperitoneally administered. Isotonic solution of sodium chloride or Penicillin was administrated to control groups. Each experimental group contained 10 mice. Intraperitoneal administration of compound (DNAase) four times a day at 500 mkg/kg dose continued for 1-3 days after infection. Penicillin was intramusculary administrated. Efficiency of action was estimated by number of animals that stayed alive after the death of the last one in control group. All animals have died to the third day of the experiment in control group. Six animals stayed alive to the third day of the experiment in the group that administrated DNase. Protection was 67%. Received data specify an opportunity and efficiency of DNase use for infections' treatment.
    • EXAMPLE 6 Level of Free Circulating Plasma DNA at Oncological Patients and Healthy Adults
  • Blood plasma DNA of oncological patients and blood plasma DNA of healthy donors differs not only by its genetic repertoire but also by its amount circulating in blood plasma. Table below presents data of blood plasma DNA contents at 10 oncological patients and at 10 healthy volunteers. DNA isolation from plasma and determination of its amount was done according to protocol mentioned above.
    DNA contents;
    Patient Sex, age Tumor, stage ng\ml
    1 M, 67 Lung carcinoma 123
    T2N2M0
    2 F, 37 Breast cancer 78
    T2N0M0
    3 F, 53 Gaster carcinoma 90
    T3N2M1
    4 M, 54 Cancer of large intestine 340
    T2N2M2
    5 M, 64 Cancer of large intestine 182
    T2N1M0
    6 M, 56 Lung carcinoma 99
    T3N2M1
    7 F, 49 Cancer of large intestine 75
    T2N1M0
    8 M, 65 Gaster carcinoma 120
    T3N1M0
    9 M, 36 Osteogenic sarcoma 243
    T3N1M2
    10 F, 50 Breast cancer 165
    T3N1M0
    11 M, 24 Volunteer 10
    12 M, 32 Volunteer 27
    13 F, 21 Volunteer 45
    14 F, 19 Volunteer 7
    15 F, 21 Volunteer 13
    16 F, 23 Volunteer 89
    17 M, 28 Volunteer 11
    18 F, 32 Volunteer 15
    19 F, 25 Volunteer 17
    20 M, 38 Volunteer 5
  • As it is clear from the table the level of volunteers' blood plasma DNA is considerably lower than in blood of patients with different malignant neoplasms.
    • EXAMPLE 7 DNA Clones' Sequences, Received from Free Circulating Blood Plasma DNA of Patient with Malignant Mesothelioma
  • Clone 1
  • Duplicon, chromosome 15 and Y
  • Sequence No 1.
  • Clone 3
  • Unique, chromosome 2.
  • Sequence No 2
  • Clone 8
  • MLT2B repeat
  • Sequence No 3
  • Clone 9
  • Centromeric satellite DNA
  • Sequence No 4
  • Clone 10
  • MLT2B repeat
  • Sequence No 5
  • Clone 20
  • L1MC4-like (LINE-element)
  • Sequence No 6
  • Clone 15
  • Alpha-satellite DNA
  • Sequence No 7
  • Clones 18, 21
  • Alpha-satellite DNA
  • Sequence No 8
  • Clone 24
  • Unique, family of G protein-bound proteins, chromosome 6.
  • Sequence No 9
  • Clone 25
  • Unique, chromosome 3.
  • Sequence No 10
  • Clone 26
  • SatB1/Vimentin/nuclear matrix binding DNA
  • Sequence No 11
  • Sequence 33
  • Duplicon specific to the chromosome 10
  • Sequence No 12
  • Clone 32
  • alpha-satellite DNA
  • Clone 35
  • LTR repeat
  • Sequence No 13
  • Clone 36
  • Unique, chromosome 18
  • Sequence No 14
  • Clone 37
  • Unique, chromosome 4
  • Sequence No 15
  • Clone 41
  • Sequence No 16
  • Clone 43
  • Snf2-related CBP activator protein (SCRAP)
  • Unique, chromosome 16
  • Sequence No 17
  • Clone 45
  • Unique, chromosome 3
  • Sequence No 18
  • Clone 47
  • Alpha-satellite DNA
  • Clone 51
  • SRY-box containing gene.
  • Sequence No 19
  • Clone 52
  • Repeat
  • Sequence No 20
  • Clone 53, 55
  • Alpha-satellite DNA
  • Sequence No 21
  • Clone 56
  • Centromeric repeat
  • Sequence No 22
  • Clone 60
  • Gene repeated on several chromosomes, contains MER5A repeat.
  • Sequence No 23
  • Clone 62
  • Repeat
  • Sequence No 24
  • Clone 65
  • Unique, chromosome 2
  • Sequence No 25
  • Clone 71
  • Unique, chromosome 2
  • Sequence No 26
  • Clone 72
  • Unique, chromosome 8
  • Sequence No 27
  • Clone 73
  • Unique
  • Sequence No 28
  • Clone 78
  • Transposon Tigger fragment
  • Sequence No 29
  • Clone 81
  • Sequence No 30
  • Repeat (LINE)
  • Clone 82
  • Unique, chromosome 1
  • Sequence No 31
  • Clone 83
  • Unique, Fibroblast activation protein alpha; cell surface serine protease
  • Chromosome 2
  • Sequence No 32
  • Clone 79
  • Alpha-satellite DNA
  • Clone 86
  • Unique, gene highly similar to brain testican, chromosome 4.
  • Sequence No 33
  • Clone 90
  • Unique, chromosome X
  • Sequence No 34
  • Clone 93
  • Unique, chromosome 9
  • Sequence No 35
  • Clones 89
    Figure US20080004561A1-20080103-P00901
    92
  • Alpha-satellite DNA
  • Clone 96
  • Fragment LINE.
  • Sequence No 36
  • Clone 97
  • Chromosome 2 unique, Lipin
  • Clone 98
  • Unique, chromosome X
  • Sequence No 38
  • Clone 102
  • Chromosome 17 unique
  • Sequence No 39
  • Clone 99
  • Alpha-satellite DNA
  • Clone 105
  • Unique, chromosome 13
  • Sequence No 40
  • Clone N106
  • Chromosome 9 unique
  • Sequence No 41
  • Clone 107
  • Unique, chromosome 8
  • Sequence No 42
  • Clone N 111
  • Unique, chromosome 12
  • Sequence No 43
  • Clone N 112
  • Chromosome 5 unique
  • Sequence No 44
  • Clone 114
  • Chromosome 8 unique; Interleukin 7
  • Sequence No 45
  • Clone 116
  • Chromosome 1 unique
  • Sequence No 46
  • Clone 121
  • Chromosome 5 unique; Dynein
  • Sequence No 47
  • Clone 115; 119; 120
  • Alpha-satellite DNA
  • Clone 125
  • Chromosome 9 unique
  • Sequence No 48
  • Clone 127
  • Unique chromosome 20
  • Sequence No 49
  • Clone 130
  • Unique, chromosome is not determined.
  • Sequence No 50
  • Clone 124
  • SatB1/Vimentin/nuclear matrix binding DNA
  • Clone 133
  • Alpha-satellite DNA
  • Clone 137
  • MLT1A2 repeat
  • Sequence No 51
  • Clone 140
  • Unique, chromosome 2; zinc finger protein, subfamily 1A
  • Sequence No 52
  • Clone 141
  • Chromosome 2 unique
  • Sequence No 53
  • Clone 143
  • Fragment of Alu-repeat
  • Sequence No 54
  • Clone 144
  • Chromosome 2 unique
  • Sequence No 55
  • Clone 146
  • Chromosome 4 unique
  • Sequence No 56
  • Clone 139 and 142
  • Alpha-satellite DNA
  • Clone 148
  • Repeat (chromosomes 1, 2 and 4)
  • Sequence No 57
  • Clone 152
  • Unique, chromosome 16; KRAB-Domain, zinc finger protein
  • Sequence No 58
  • Clone 154
  • Chromosome 9 unique
  • Sequence No 59
  • Clone 161
  • Fragment LINE
  • Sequence No 60
  • Clone 151
  • Chromosome 5 unique
  • Sequence No 61
  • Clone 150
  • Chromosome 1 unique
  • Sequence No 62
  • Clone 153
  • Chromosome 11 unique
  • Sequence No 63
  • Clone 159
  • Chromosome 6 unique
  • Sequence No 64
  • Clone 163
  • Alpha satellite DNA
  • Sequence No 65
  • Clone 166
  • Chromosome 12 unique
  • Sequence No 66
  • Clone 167
  • Unique, chromosome 18, CDH2; cadherin 2, type 1, N-cadherin
  • Sequence No 67
  • Clones 169, 170
  • Chromosome 18 unique
  • Sequence No 68
  • Clone 178
  • Unique chromosome 1; RAMP: RA-regulated nuclear matrix-associated protein
  • Sequence No 69
  • Clone 180
  • Unique, chromosome 20
  • Sequence No 70
  • Clone 181
  • Unique chromosome 18
  • Sequence No 71
  • Clone 185
  • Alpha-satellite DNA
  • Sequence No 72
  • Clone 187
  • Mer repeat
  • Sequence No 73
  • Clone 188
  • HSATII repeat
  • Sequence No 74
  • Clone 189
  • Chromosome 9 unique
  • Sequence No 75
  • Clone 190
  • Chromosome 1 unique; melanoma antigen recognized by T cells 2
  • Sequence No 76
  • Clone 195
  • Chromosome 10 unique
  • Sequence No 77
  • Clone 196
  • Chromosome X unique
  • Sequence No 78
  • Clone 197
  • Chromosome 1 unique, FAF 1: Fas (TNFRSF6) associated factor 1
  • Sequence No 79
  • Clone 200
  • Chromosome 8 unique
  • Sequence No 80
  • Clone 202
  • Unique chromosome 13
  • Sequence No 81
  • Clone 205
  • Alpha satellite DNA
  • Sequence No 82
  • Clone 206
  • Repeat
  • Sequence No 83
  • Clone 208
  • Unique chromosome 8; Human DEAD box RNA helicase-like protein
  • Sequence No 84
    • EXAMPLE 8 DNA Clones Sequences Received From Free Circulating Blood Plasma DNA of Healthy Donor
  • Clone 1
  • Chromosome 5 unique
  • Sequence No 85
  • Clone 9
  • Unique chromosome 21
  • Sequence No 86
  • Clone 7
  • Unique chromosome 3
  • Sequence No 87
  • Clone 8
  • Chromosome 4 unique
  • Sequence No 88
  • Clone 10
  • 18S RNA gene
  • Sequence No 89
  • Clone 11
  • Alu repeat
  • Sequence No 90
  • Clone 13
  • Unique chromosome 3
  • Sequence No 91
  • Clone 15
  • Unique chromosome 1
  • Sequence No 92
  • Clone 16
  • Unique chromosome 3, neutral endopeptidase
  • Sequence No 93
  • Clone 17
  • Chromosome 8 unique
  • Sequence No 94
  • Clone 18
  • Chromosome 1 unique
  • Sequence No 95
  • Clone 21
  • Unique chromosome 19; Zinc Finger protein
  • Sequence No 96
  • Clone 22
  • Unique chromosome 18
  • Sequence No 97
  • Clone 23
  • Unique chromosome 7, muskelin 1
  • Sequence No 98
  • Clone 25
  • Unique chromosome 11
  • Sequence No 99
  • Clone 27
  • Repeat
  • Sequence No 100
  • Clone 29
  • Unique chromosome 6
  • Sequence No 101
  • Clone 30
  • Unique chromosome 14
  • Sequence No 102
  • Clone 31
  • Unique chromosome 17
  • Sequence No 103
  • Clone 32
  • MER4B repeat
  • Sequence No 104
  • Clone 33
  • Chromosome 1 unique
  • Sequence 105
  • Clone 34
  • Unique chromosome 2
  • Sequence 106
  • Clone 35
  • Repeat
  • Sequence 107
  • Clone 36
  • Chromosome 1 unique
  • Sequence No 108
  • Clone 37
  • HERVH repeat
  • Sequence No 109
  • Clone 41
  • Chromosome X unique
  • Sequence No 110
  • Clone 42
  • Chromosome 6 unique
  • Sequence No 111
  • Clone 43
  • Unique chromosome 22; KREMEN1
  • Sequence No 112
  • Clone 44
  • Unique chromosome 14
  • Sequence No 113
  • Clone 45
  • Unique
  • Sequence No 114
  • Clone 46
  • Chromosome 20 unique
  • Sequence No 115
  • Clone 47
  • Nf-kappaB
  • Sequence No 116
  • Clone 38
  • Unique chromosome 16
  • Sequence No 117
  • Clone 48
  • Chromosome 6 unique
  • Sequence No 118
  • Clone 53
  • Unique
  • Sequence No 119
  • Clone 51
  • Chromosome 5 que
  • Sequence No 120
  • Clone 59
  • Unique chromosome 4, NFKB 1: nuclear factor of kappa light polypeptide gene enhancer
  • Sequence No 121
  • Clone 61
  • Repeat
  • Sequence No 122
  • Clone 62
  • L1 repeat
  • Sequence No 123
  • Clone 64
  • Duplicon chromosome 7
  • Sequence No 124
  • Clone 65
  • Ribosomal DNA
  • Sequence No 125
  • Clone 66
  • Rbosomal DNA
  • Sequence No 126
  • Clone 75
  • Repeat
  • Sequence No 127
  • Clone 76
  • Chromosome 4 unique
  • Sequence No 128
  • Clone 83
  • Chromosome 4 unique
  • Sequence No 129
  • Clone 85
  • Unique chromosome 2; phospholipase C, epsilon
  • Sequence No 130
  • Clone 87
  • L1PA3 repeat
  • Sequence No 131
  • Clone 86
  • Unique chromosome 5; CRTL 1: cartilage linking protein 1
  • Sequence No 132
  • Clone 89
  • Alu repeat
  • Sequence No 133
  • Figure US20080004561A1-20080103-P00902
    OH 92
  • Unique chromosome 6
  • Sequence No 134
  • Clone 100
  • Unique, chromosome 6
  • Sequence No 135
  • Clone 105
  • AluSx repeat
  • Sequence No 136
  • Clone 111
  • Alphoid repetitive DNA
  • Sequence No 137
  • Clone 112
  • Chromosome 9 unique
  • Sequence No 138
  • Clone 113
  • Chromosome 22 unique
  • Sequence No 139
  • Clone 114
  • AluSx repeat
  • Sequence No 140
  • Clone 116
  • Unique chromosome 9; 17 kD fetal brain protein
  • Sequence No 141
  • Clone 123
  • Unique chromosome 5
  • Sequence No 142
  • Clone 124
  • Unique chromosome 13
  • Sequence No 143
  • Clone 126
  • Unique chromosome 8
  • Sequence No 144
  • Clone 130
  • Unique chromosome 1
  • Sequence No 145
  • Clone 131
  • Unique chromosome 4
  • Sequence No 146
  • Clone 136
  • Unique chromosome 8
  • Sequence No 147
  • Clone 141
  • Unique chromosome 2
  • Sequence No 148
  • Clone 146
  • Unique chromosome 16
  • Sequence No 149
  • Clone 147
  • Unique chromosome 5; nicotinamide nucleotide transhydrogenase
  • Sequence No 150
  • Clone 149
  • Unique chromosome 9
  • Sequence No 151
  • Clone 151
  • Unique chromosome 16
  • Sequence No 152
  • Clone 152
  • Unique chromosome 6, BAI3: brain-specific angiogenesis inhibitor 3
  • Sequence No 153
  • Clone 153
  • Unique chromosome 9, GAD2: glutamate decarboxylase 2
  • Sequence No 154
  • Clone 155
  • Unique chromosome 9
  • Sequence No 155
    • EXAMPLE 9 Sensitivity of Circulating Blood DNA to DNase Action
  • DNA from fresh blood serum (mixture of blood received from 5 volunteers ) was isolated by standard phenol-chloroform method.
  • Sediment of nucleic acids was washed by 70% ethanol and dissolved in tris-EDTA buffer. Spectrophotometry with wave's length 260 nm (SF-46) was used for quantification of DNA. DNA was researched by electrophoresis in 0.8% polyacrylamide gel with ethidium bromide staining. One part of received DNA was processed by DNase I for 3 hours at 37° C. After electrophoretic separation of processed and not processed DNA it was found out that:
  • After electrophoresis non-processed DNA constitute one compact band. This factor indicates on relatively identical size of DNA circulating in blood. Said band disappeared completely after DNAse processing. Received data indicates that DNA circulating in serum is sensitive to DNases use and can be destroyed by their action.
    • EXAMPLE 10 Results of the Experiment of Influence of Polyclonal Serum Containing Anti-DNA Antibodies' on Life Span of Erlich Carcinoma Bearing Mice
  • DNA circulating in blood plasma of oncological patients can be destroyed or inactivated not only by DNA—digesting enzymes (for example by DNase), but also by other methods.
  • Anti-DNA antibodies were isolated from blood of patients with lupus erythematosus by Shuster A. M. method (Shuster A. M. et. al., Science, v. 256, 1992, pp. 665-667). Such anti-DNA antibodies were capable not only to bind DNA but also to hydrolyze it.
  • Group 1—7 mice transplanted with Erlich carcinoma (control).
  • Group 2—6 mice transplanted withy Erlich carcinoma. Mice were injected intravenously with fraction of human anti-DNA antibodies (Ig G) at 200 mkg dose on the third day after tumor transplantation.
  • Group 3—6 mice transplanted withy Erlich carcinoma. Mice were injected intravenously with fraction of human non specific immunoglobulin (Ig G) at 200 mkg dose on the third day after tumor transplantation.
  • Effect was estimated according to tumor's growth inhibition on the 7th day after transplantation (TGO expressed in percents).
  • Tumor's on the 7th day after transplantation.
    Group Tumor's volume T% P
    1  85 +/− 12 — —
    2 45 +/− 6 52% p < 0.001
    3 79 +/− 7  7% p < 0.001
  • Results of experiments indicates that single anti-DNA antibodies' administration possess strong antitumor effect. Administration of antibodies fraction that does not contain ant-DNA antibodies do not possess antitumor activity.
    • EXAMPLE 11 Effect of Mice' Vaccination by Blood Plasma DNA Fraction Received from Animals with Erlich Carcinoma on Transplantation and Growth of Erlich Carcinoma at Immunized Animals
  • DNA from plasma of mice with Erlich carcinoma was isolated on the 5th day after transplantation according to method mentioned above. Positively charged multilayer liposomes were used as adjuvants for immunization. DNA sample was mixed with liposomes (20 mkg of DNA in 1 mg of lipids).
  • Group 1—6 non immunized mice.
  • Group 2—6 mice immunized for three times with one week 5 interval by intradermal administration of 1 mkg DNA from blood plasma in 50 mkl of liposomal suspension containing 50 mkg of liposomes.
  • Group 3—6 mice immunized for three times with one week interval by intradermal administration of 50 mkl of liposomal suspension containing 50 mkg of liposomes without DNA.
  • Group 4—6 mice immunized for three times with one week interval by intradermal administration of 1 mkg DNA from calf thymus (Sigma) in 50 mkl of liposomal suspension containing 50 mkg of liposomes.
  • One week after the last immunization Erlich carcinoma was transplanted to all mice including non immunized control mice.
  • Results of the experiment were estimated according to animal survival on the 30th and 50th day after tumor's transplantation.
    30 day 50 day
    (number of alive\ (number of alive\
    number of dead in number of dead in
    Group group) group)
    1 0-6 0-6
    2 5-6 3-6
    3 0-6 0-6
    4 2-6 0-6
  • So immunization of mice with replanted Erlich carcinoma by blood plasma DNA lead to significant increasing of animals' lifetime.
    • EXAMPLE 12 DNA Isolation from Biofilm Matrix Formed by Gram-Positive and Gram-Negative Bacteria
  • Biofilms of Escherichia coli and Staphylococcus aureus were used in experiments. Biofilms were washed off by phosphate buffer from agar. Cells and matrix were separated by centrifuging. Standard phenol-chloroform method was used for DNA extraction from matrix. DNA amount was estimated by spectrophotometric analysis with wave's length 260 nm (SF-46). Received DNA was researched by electrophoresis in 0.8% polyacrylamide gel with ethidium bromide staining.
  • One part of received DNA was processed for 3 hours by DNAase I at 37° C. After electrophoretic separation of processed and not processed DNA it was found out that:
  • After electrophoresis non-processed DNA form one compact line. This fact indicates relatively identical size of DNA in biofilm matrix. Said band disappeared completely after DNAse processing. So the biofilm matrix of gram positive and gram negative bacteria contains extracellular DNA, which could be destroyed with DNAse.
    • EXAMPLE 13 Dynamics of P-Glycoprotein Expression in Erlich Carcinoma at Mice that Receive Doxorubicin Therapy and DNase I Effect
  • Treatment by Doxorubicin causes expression of P-glycoprotein in tumor tissue that is one of the main MDR (Multidrug Resistance) phenotype mediators. Immunohistochemical staining of mice's tumor histological cuts are listed below.
  • Mice were subjected to course of 5 day therapy with Doxorubicin (2 mg/kg intravenously daily) or Doxorubicin+DNase I (0.5 mg/kg four times a day during 5 days)
  • Treatment has begun on the 3rd day after tumor's transplantation. Tissue preparations were executed on the 8th day of tumor's transplantation. Multifocal expression of P-glycoprotein was observed in tumor tissue after 5 days of therapy (FIG. 1).
  • Total level of P-glycoprotein expression and amount of P-glycoprotein positive nodules in tumor tissue was much lower at the case of combined treatment by Doxorubicin+DNase (FIG. 1). So treatment by DNase delays development of multidrug resistant phenotype in tumor that is caused by antitumor antibiotic Doxorubicin use.
    • EXAMPLE 14 Influence of Plasma DNA of C57B1 Mice with LLC Tumor After Chemotherapeutical Treatment by Doxorubicin, on LLC Tumor Growth and Metastasizes Development at C57B1 Mice Receiving Doxorubicin Therapy and Effect of DNase I
  • LLC tumor was replanted to 30 C57B1 mice. Twenty mice were treated with Doxorubicin at 2 mg/kg dose daily for 5 days, starting day 3 after transplantation. Ten mice were treated with Cyclophosphamide at 15 mg/kg dose intraperitoneally for once on the 3rd day after replantation. Such treatment scheme does not lead to animal's recovery but leads to 50% tumor inhibition at day 8 in doxorubicin treated animals and 30% tumor inhibition at day 8 in Cyclophosphamide treated animals. On the next day after end of chemotherapy course animals were euthanized and and total blood plasma from both mice groups was taken. After isolation total fraction of blood plasma DNA was stored at −20° C. in phosphate buffer.
  • Five groups of mice that were transplanted with LLC tumor participated in experiment.
  • Group 1—7 mice (control).
  • Group 2—6 mice intravenously treated with Doxorubicin chemotherapy from 3rd up to 8th day at 2 mg/kg dose daily.
  • Group 3—6 mice intravenously treated with Doxorubicin chemotherapy from 3rd up to 8th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to Doxorubicin chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)
  • Group 4-6 mice intravenously treated with Doxorubicin chemotherapy from 3rd up to 8th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to cyclophosphamide chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)
  • Group 5—6 mice intravenously treated with Doxorubicin chemotherapy from 3rd up to 8th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to Doxorubicin chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)+intraperitoneal administration of DNase I at 0.5 mg/kg dose for 4 times a day at the first and second days of treatment.
  • Tumor's size on the 8th day after transplantation.
    Group Tumor's size
    1 127+/−13
    2 67 +/− 7
    3 115 +/− 20
    4  75 +/− 11
    5 82 +/− 9
  • So administration of blood plasma DNA from mice subjected to chemotherapy lead to tumor's resistance to chemotherapeutic treatment. DNase's administration prevents appearance of this effect.
    • EXAMPLE 15 Influence of Blood Plasma DNA from C57B1 Mice with Highly Metastatic LLC Strain on Metastasizing of Low Metastatic LLC Tumor Strain in C57B1 Mice and Effect of DNase I
  • LLC tumor was transplanted to 30 C57B1 mice. Twenty mice were transplanted with highly metastatic strain and 10 mice were transplanted with low metastatic strain. On the 9th day animals were euthanized and total blood plasma of both mice groups was collected. After isolation the total fraction of blood plasma DNA was stored at −20° C. in phosphate buffer.
  • Five groups of mice with transplanted LLC tumor participated in the experiment.
  • 1 Group—6 mice transplanted with low metastatic LLC strain.
  • 2 Group—6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted highly metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7th and 8th day after transplantation).
  • 3 Group—6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted low metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7th and 8th day after transplantation)
  • 4 Group—6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted highly metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7th and 8th day after transplantation)+intraperitoneal administration of DNase I at 1 mg/kg dose two times daily at 7th and 8th day after transplantation.
  • 5 Group—6 mice transplanted with highly metastatic LLC strain.
  • Number of metastatic foci in lungs was estimated bon the 15th day after transplantation (N).
  • Experiments' results are presented in the table.
    Group N
    1 12, 0
    2 24, 1
    3 14, 6
    4 11, 6
    5 33, 6
  • Received data indicates that blood plasma DNA from mice with highly metastatic LLC strain intensify metastasizing of low metastatic LLC strain.
  • DNase administration prevents appearance of this effect.
    • EXAMPLE 16 DNase I Influence on Life Span of C57B1 Mice Transplanted with LLC Tumor (Highly Metastatic Strain)
  • Five groups of LLC transplanted mice participated in the experiment.
  • Group 1—7 mice (control).
  • Group 2—6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 7 day after tumor transplantation.
  • Group 3—6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 10 day after tumor transplantation.
  • Group 4—6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 15 day after tumor transplantation.
  • Group 5—6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 18 day after tumor transplantation.
  • Results of experiment were estimated according to animals' survival on the 30 and 50 day after tumor transplantation.
    30 day 50 day
    (number of alive\ (number of alive\
    number of dead in number of dead in
    Group group) group)
    1 0-7 0-7
    2 0-6 0-6
    3 3-6 0-6
    4 5-1 3-3
    5 6-0 6-0
  • The significant inhibition of tumor's growth was observed at the last day of DNase treatment in the 2nd and 3rd groups, but tumor's growth renewed after DNase withdrawal and to the 25th day size of tumor in this groups and in control has equalized.
  • The most longitudinal course o DNase treatment (from 3rd up to 18th day—group number 6) has lead to maximal survival. Inhibition of tumor growth was more than 95% at day 18.
  • In all experiments single and multiple injection of up to 2.5 mg/kg of human DNase I (maximal dose that was used in experiments) had no toxic effect on animals.
  • So, DNase I does not cause direct cytotoxic effect on tumor cells (in our in vitro experiments at concentration of 100 mkg/ml) and experimental data confirm that antitumor effect is connected with destruction of DNA in blood plasma and DNase's therapeutic effect increases with increasing of its treatment course duration.
    • EXAMPLE 17 Influence of Different Methods of Blood Plasma DNA's Destruction, Inactivation, and Binding on Ability of Blood Plasma DNA from C57B1 Mice with Transplanted Highly Metastatic LLC Strain to Intensify Metastasizing of Low Metastatic LLC Tumor Strain in C57B1 Mice
  • 100 mice were transplanted with highly metastatic LLC strain. On the 9th day after transplantation, animals were euthanized and total blood plasma was taken. After isolation total fraction of blood plasma DNA was stored at −20° C. in phosphate buffer.
  • Six groups of mice with transplanted low metastatic LLC strain participated in the experiment.
  • Group 1—6 mice transplanted with low metastatic LLC strain.
  • Group 2—6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection).
  • Group 3—6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection). Before administration the sample was photochemically disinfected (1 mkM of methylene blue was added with following irradiation by red light during 10 minutes (60 000 Lux).
  • Group 4—6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection). The sample was passed through the column containing DEAE-cellulose for two times before administration.
  • Group 5—6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection. 1 mkg of fragment A of Ricin toxin was added to the sample before administration and sample was incubated at 370C for 1 hour. Ricin toxin is representative of RIP toxins family (proteins that inactivate ribosomes) which are used for immunotoxin's creation. Besides their ability to inactivate ribosomes these proteins can deadenylate DNA. For realization of toxic effect catalytic subunit A of RIP II type should by delivered to cell by B subunit. Without B subunit A chain is not toxic but can be used for blood plasma DNA's inactivation due to its polynucleotide-adenylglicozidase activity.
  • Group 6—6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection. Total DNA fraction was enzymatically methylated before administration (I. Muiznieks et. al., FEBS Letters, 1994, v. 344, pp. 251-254).
  • Number of metastaic nodules in lungs was estimated on the 15th day after transplantation.
  • Results of the experiments are presented in the table.
    Group Ncp.
    1 12, 0
    2 22, 5
    3 14, 1
    4 15, 5
    5 15, 1
    6 12, 3
  • Received data indicates that all used methods inhibited ability of blood plasma DNA of mice with highly metastatic LLC tumor strain to increase metastasizing process of low metastatic LLC tumor strain.
    • EXAMPLE 18 Influence of DNase I Therapy on the Development of Somatic Mosaicism
  • Frequency of HPRT gene's mutations in blood T-lymphocytes was studied as a model of somatic mosaicism. Human HPRT gene (chromosome Xq26) encodes enzyme that is constitutionally expressing but not essential and is involved in metabolism of purine nucleotides. Cloning was done according to Bigbee W. method (Bigbee W. Et al., Mutation Res., 1998, v. 397, pp. 119-136).
  • Lymphocytes from peripheral blood of 8 patients subjected to 3 week course of immunostimulating therapy by Neovir after surgical elimination of tumor were used for cloning. 4 patients out from 8 were additionally subjected to intravenous administration of human recombinant DNase I (200 mkg/kg dose 4 times a day during three weeks).
  • Incidence of HPRT—deficient clones in the blood of patients that received DNase I therapy was 3 times less than in blood of patients that received only immunostimulating therapy.
    • EXAMPLE 19 Influence of DNase I Therapy on Old Rats' Life Time
  • White not thoroughbred 24 month old rats were used in experiment. In the study group (10 animals) rats starting from the age of 24 months were subjected to intravenous administration of polysialated human DNase I at 500 mg/kg (equivalent dose of non-modified enzyme) 2 times a week during 2 months. Control group of animals got the administration of placebo. Average life time of rats from control group was 27.8 months. Average life time of rats from experimental group was 30.1 months.
    • EXAMPLE 20 Influence of DNase I Therapy on Viability of Pancreatic {tilde over (β)} Cells and Endothelium of Aorta
  • {tilde over (β)} cells of human embryonic pancreas and endothelial cells of human aorta were used for primary cell culture formation. DNA isolated from plasma of patient with severe II-type diabetes complicated by systemic atherosclerosis (0.0025 mkg per 1 ml of culture media) was added to cell culture 24 hours after passage.
  • In other experimental series DNA of the patient before introduction to cell culture was processed with enzymatic methylation. Amount of viable cells was estimated 24 hours later with trypan blue staining.
  • Results of experiment are presented in the table.
  • Percentage of viable cells 48 hours after subculturing.
    Cells Control Patient's DNA Methylated DNA
    B-cells 73% 43% 61%
    Endothelium 62% 35% 55%
    • INDUSTRIAL APPLICABILITY
  • Current invention justify that destruction (binding, inactivation) of circulating blood plasma DNA in course of oncological and bacterial diseases possess significant therapeutic effect.
  • Invention is confirmed by the fact that blood plasma DNA of patients contains unique genes that takes part in formation and maintenance of tumor's “malignant phenotype”.
  • Binding, destruction or inactivation of DNA circulating in blood plasma possess therapeutic effect at diseases which development is connected with accumulation and spreading of somatic mutations in host's cells.
  • Blood plasma circulating DNA can be destructed, inactivated or eliminated from blood plasma by DNases, sorbents, antibodies and other methods which provide inactivation by destroying, binding or modification of circulating DNA.
  • Treatment directed to the destruction of blood plasma DNA lead to significant antitumor effect while its own toxicity is immaterial.
  • Treatment directed to the destruction of blood plasma DNA if combined with traditional antitumor therapy lead to significant antitumor effect.
  • Efficiency of the treatment directed to blood plasma DNA's destruction can be estimated by monitoring of DNA amount and amount of tumor's genetic markers in blood plasma of patient who receive such therapy.
  • Cloning and sequencing of blood plasma DNA from oncological patient's can be used for studying of genetic processes that take part in oncogenesis and identification of new genes connected with oncogenesis processes.
  • Cloning and sequencing of healthy people's blood plasma DNA can be used for studying of genome's operating in healthy individual and in the development of somatic diseases and in identification of new genes that are involved in these processes.
  • Pharmaceutical compositions containing components that inactivate by destroying, binding and modification the blood plasma DNA could be used for treatment of patients with oncological diseases, infections, somatic diseases and for prolongation of life time.
  • For providing effective therapeutic exposition of active component that is necessary for blood plasma DNA' destruction, and for therapeutic effect achievement pharmaceutically acceptable compositions and modifications, drug delivery systems are used providing maximal systemic circulations of the active component in blood plasma and its contact with DNA circulating in plasma. The main way of administration is intravenous. But other ways of administration that provide coming of active component in to systemic circulation, such as subcutaneous, intramuscular, inhalation, intraperitoneal and others can also be used. Doses and regimes of administration are determined by nature of used active ingredient and way of administration. The effect is controlled by the level of DNA's contents and its dynamics in blood plasma, presence of tumor, infectious and other genetic markers, and appearing of positive clinical dynamics of disease.

Claims (22)

1. Treatment method of oncological and/or infectious and/or somatic diseases by acting on biological targets inside organisms, differs in that the biological target is extracellular DNA including extracellular DNA circulating in blood plasma.
2. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1 differs in that the extracellular DNA is inactivated by destruction, binding or modification.
3. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1 and 2, differs in that the extracellular DNA is inactivated by destruction, binding or modification by injecting to patient of pharmaceutical agent which is capable to destroy, bind or modify free circulating DNA.
4. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1-3, differs in that the extracellular DNA is inactivated by destruction, binding or modification by pharmaceutical agent's injection in amount sufficient for destruction and in therapeutic regime providing destruction, binding or modification in sufficient for therapeutic effect achievement period of time.
5. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1-4 differs in that the genetically modified cells or genotherapeutic constructions are injected to patient when said remedies induce synthesis in host's organism of biopolymers, capable to inactivate free circulating blood plasma DNA by its binding, destruction or modification.
6. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1 or 2, differs in that the circulating extracellular DNA is inactivated by destruction, binding or modification using extracorporeal blood processing.
7. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1, 2 or 6, differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by immune or affine absorption.
8. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1, 2 or 6, differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by methods of gravitational blood surgery.
9. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1, 2 or 6, differs in that the extracorporal purification of patient's blood from free circulating DNA is achieved by biological, chemical or photochemical inactivation.
10. Treatment method of oncological and/or infectious and/or somatic diseases according claim 1 or 2, differs in that the patient is immunized by vaccine, which vaccine contain blood plasma circulating DNA (including said DNA with naturally complexed proteins) as the antigen.
11. Treatment method of oncological and/or infectious and/or somatic diseases according claims 1-10, differs in that the treatment is combined with surgical, chemiotherapeutic, hormonal, radiation and immunotherapeutic methods.
12. Pharmaceutical agent for oncological and/or infectious and/or somatic disease treatment, representing compound possessing desoxyribonuclease activity and/or being able to inactivate extracellular DNA including DNA circulating in patients blood plasma.
13. Pharmaceutical agent according claim 12 differs in that compound possessing desoxyribonuclease activity is desoxyribonuclease enzyme.
14. Pharmaceutical agent according claim 13 differs in that desoxyribonuclease is modified for better pharmacodynamic and pharmacokinetic performance and comprises desoxyribonuclease analogue with increased activity, desoxyribonuclease analogue not sensitive to endogenous inhibitors of desoxyribonuclease, polysialated desoxyribonuclease, pegylated desoxyribonuclease, desoxyribonuclease that is bound or mixed with synthetic and natural microspheres, liposomes, dextran, and other corpuscular natural and synthetic polymer carriers.
15. Pharmaceutical agent according claims 12-14 which additionally contains ribonuclease and/or lipase and/or proteinase.
16. Pharmaceutical agent according claim 12, differs in that the compound possessing desoxyribonuclease activity is antibody possessing nuclease activity, in particular polyclonal DNA-abzymes, monoclonal DNA-abzymes or their derivatives.
17. Pharmaceutical agent according claim 12, differs in that the compound able to bind DNA is antibody able to bind DNA and its complexes and derivatives of said antibody.
18. Pharmaceutical composition for oncological and infectious diseases treatment, containing pharmaceutical agent according claims 12-16 in therapeutically effective amount and pharmaceutically acceptable carrier or excipient.
19. Method to increase the life time which is achieved by inactivation of extracellular DNA circulating in blood plasma by said DNA destruction, binding or modification according claims 2-17.
20. Method of prophylaxis of pathologies connected with appearance and development of somatic mosaicism by the way of destruction, binding or modification of DNA according to claims 2-17.
21. Method to control the treatment efficacy of oncological and/or infectious and somatic diseases, to estimate the infection development, to control the efficacy of treatment directed to prolongation of life time, by the way of measurement of patient biochemical factors, differs in that monitoring for control of such treatment sizes of molecules, fractions' correlation, bindings with proteins, lipids and sugars, nucleotide consequences of free circulating blood plasma DNA are used.
22. Usage of blood plasma DNA and extracellular microbial DNA for evaluation of DNA involved in process of diseases' appearance and development, which usage includes its cloning, sequencing, identification of genes, unique and repeated sequences with their future studying.
US10/564,615 2003-07-14 2005-01-27 Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment Abandoned US20080004561A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/RU2003/000304 WO2005007187A1 (en) 2003-07-14 2003-07-14 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2004108061/14A RU2269356C2 (en) 2003-07-14 2004-03-12 Method for treating oncological patients

Publications (1)

Publication Number Publication Date
US20080004561A1 true US20080004561A1 (en) 2008-01-03

Family

ID=34067504

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/564,861 Active 2025-07-06 US7612032B2 (en) 2003-07-14 2004-07-01 Method for treating oncological diseases
US10/564,615 Abandoned US20080004561A1 (en) 2003-07-14 2005-01-27 Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/564,861 Active 2025-07-06 US7612032B2 (en) 2003-07-14 2004-07-01 Method for treating oncological diseases

Country Status (6)

Country Link
US (2) US7612032B2 (en)
EP (1) EP1655036B1 (en)
ES (1) ES2427091T3 (en)
PL (1) PL1655036T3 (en)
RU (1) RU2269356C2 (en)
WO (1) WO2005004903A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053200A1 (en) * 2005-04-25 2009-02-26 Dmitry Dmitrievich Genkin Method for retarding unhealth manifestations brought by ageing of human beings
US20100061971A1 (en) * 2006-11-28 2010-03-11 Dmitry Dmitrievich Genkin Method for Treating Human Diseases Associated With an Increased Deoxyribonucleic Acid Content in Extracellular Spaces of Tissues and a Medicinal Preparation for Carrying Out Said Method
US20100150903A1 (en) * 2003-07-14 2010-06-17 Dmitry Dmitrievich Genkin Method for Treating Oncological Diseases
US20100303796A1 (en) * 2003-07-14 2010-12-02 Dmitry Dmitrievich Genkin Method for Treating Systemic DNA Mutation Disease
WO2013114373A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Inhalable liquid formulations of dnase i
US20140050723A1 (en) * 2011-04-01 2014-02-20 The Regents Of The University Of California Cell-Penetrating Anti-DNA Antibodies and Uses Thereof Inhibit DNA Repair
US9072733B2 (en) 2003-07-14 2015-07-07 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
WO2022214966A1 (en) * 2021-04-05 2022-10-13 Victor Tets Regulation of cells and organisms
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
US11724015B2 (en) 2017-09-18 2023-08-15 Santersus Ag Method and device for purification of blood from circulating cell free DNA
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007187A1 (en) * 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
GB0713074D0 (en) 2007-07-05 2007-08-15 Univ London A method of hyperpolarising a magnetic resonance agent
US20110159569A1 (en) * 2008-04-30 2011-06-30 Ajou University IndustryAcademic Cooperation Found Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2012071420A1 (en) * 2010-11-23 2012-05-31 The Trustees Of Columbia University In The City Of New York Enzyme combinations to reduce brain tissue swelling
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
GB201208879D0 (en) * 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
DE102016001407A1 (en) 2016-02-09 2017-08-24 Fresenius Medical Care Deutschland Gmbh Blood treatment with inactivation of free nucleic acids
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
AU2018318313A1 (en) 2017-08-18 2020-03-19 Neutrolis Inc.. Engineered DNase enzymes and use in therapy
WO2019212694A1 (en) * 2018-04-30 2019-11-07 Viktor Veniaminovich Tets Tetz-proteins and prion-like proteins and associated methods
US11918610B2 (en) 2018-06-29 2024-03-05 Viktor Veniaminovich Tets Methods for diagnosis and treatment of type 1 diabetes
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
EP3864147A4 (en) 2018-10-08 2022-07-06 Neutrolis, Inc. Engineering of dnase enzymes for manufacturing and therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
JP2023545740A (en) 2020-10-07 2023-10-31 プロタリクス リミテッド Long-term active DNase
EP4340682A1 (en) * 2021-05-21 2024-03-27 Dmitry Dmitrievich Genkin Immunomodulation of tumor microenvironment
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521409B1 (en) * 1996-03-15 2003-02-18 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
CH686982A5 (en) 1993-12-16 1996-08-15 Maurice Stroun Method for diagnosis of cancers.
RU2099080C1 (en) * 1994-02-11 1997-12-20 Дмитрий Иванович Финько Method for preventing from cancer development
AU762972B2 (en) * 1998-07-16 2003-07-10 Research Development Foundation Novel DNA-cleaving antitumor agents
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521409B1 (en) * 1996-03-15 2003-02-18 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770492B2 (en) 2003-07-14 2017-09-26 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8796004B2 (en) 2003-07-14 2014-08-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US20100150903A1 (en) * 2003-07-14 2010-06-17 Dmitry Dmitrievich Genkin Method for Treating Oncological Diseases
US20100303796A1 (en) * 2003-07-14 2010-12-02 Dmitry Dmitrievich Genkin Method for Treating Systemic DNA Mutation Disease
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9845461B2 (en) 2003-07-14 2017-12-19 Cls Therapeutics Limited Method for treating oncological diseases
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US9072733B2 (en) 2003-07-14 2015-07-07 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9463223B2 (en) 2003-07-14 2016-10-11 Cls Therapeutics Limited Method for monitoring development of somatic mosaicism
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8535663B2 (en) 2003-07-14 2013-09-17 Cls Therapeutics Limited Method for treating delayed-type hypersensitivity
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US20090053200A1 (en) * 2005-04-25 2009-02-26 Dmitry Dmitrievich Genkin Method for retarding unhealth manifestations brought by ageing of human beings
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US20100061971A1 (en) * 2006-11-28 2010-03-11 Dmitry Dmitrievich Genkin Method for Treating Human Diseases Associated With an Increased Deoxyribonucleic Acid Content in Extracellular Spaces of Tissues and a Medicinal Preparation for Carrying Out Said Method
US20140050723A1 (en) * 2011-04-01 2014-02-20 The Regents Of The University Of California Cell-Penetrating Anti-DNA Antibodies and Uses Thereof Inhibit DNA Repair
US10961301B2 (en) 2011-04-01 2021-03-30 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
US9701740B2 (en) * 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013114373A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Inhalable liquid formulations of dnase i
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US11724015B2 (en) 2017-09-18 2023-08-15 Santersus Ag Method and device for purification of blood from circulating cell free DNA
US11771811B2 (en) 2017-09-18 2023-10-03 Santersus Ag Method and device for purification of blood from circulating cell free DNA
US11771812B2 (en) 2017-09-18 2023-10-03 Santersus Ag Method and device for purification of blood from circulating cell free DNA
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2022214966A1 (en) * 2021-04-05 2022-10-13 Victor Tets Regulation of cells and organisms

Also Published As

Publication number Publication date
RU2269356C2 (en) 2006-02-10
ES2427091T3 (en) 2013-10-28
EP1655036A4 (en) 2009-06-17
RU2004108061A (en) 2005-09-27
WO2005004903A1 (en) 2005-01-20
EP1655036B1 (en) 2013-07-17
PL1655036T3 (en) 2014-02-28
US7612032B2 (en) 2009-11-03
US20060233780A1 (en) 2006-10-19
EP1655036A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
US20080004561A1 (en) Method for Treating Oncological, Virulent and Somatic Diseases, Method for Controlling Treatment Efficiency, Pharmaceutical Agents and Composition for Carrying Out Said Treatment
EP1666055A1 (en) Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
US9463223B2 (en) Method for monitoring development of somatic mosaicism
US9845461B2 (en) Method for treating oncological diseases
US8916151B2 (en) Method for treating a reduction of fertility
Tomcsányi et al. Processing enzyme ribonuclease E specifically cleaves RNA I: an inhibitor of primer formation in plasmid DNA synthesis
WEIsS et al. Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli.
US20240117364A1 (en) Synthetic immunomodulation with a crispr super-repressor in vivo
JPH0193537A (en) Inhibitor of angiogenine
EP3277813B1 (en) Novel therapy
RU2269359C2 (en) Method for prophylaxis of oncological diseases, or infections mordibidized by bacteria or fungi and protozoa, or arteriosclerosis, or diabetes mellitus, or diseases mediated by delayed hyperresponsiveness reaction, or diseases mediated by somatic cell gene mutations (variants)
EP2497487B1 (en) Method for treating diabetes and atherosclerosis associated with changes of qualitative and/quantitative composition of blood extracellular DNA
Schirm et al. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C‐terminal peptides eliminate serum‐resistant Escherichia coli from blood cultures
Babina et al. Lactoferrin is the major deoxyribonuclease of human milk
US11058756B2 (en) Compositions and methods of treating autoimmune disease by reducing enterococcus
Halpern et al. Inhibition of neoplastic cell growth by autogenous DNA.
WO2024020484A2 (en) Biallelic knockout of angptl3
Deutsch et al. Molecular Etiopathogenesis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue
CA3217356A1 (en) Engineering b cell-based protein factories to treat serious diseases
JPH09157160A (en) Inactivation inhibitor of virus vector
Matsuo et al. Complement-mediated renal injury: Mechanisms and role of membrane regulators of complement

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION